gabapentin has been researched along with Aura in 261 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gabapentin as monotherapy probably controlled seizures no better and no worse than comparator AEDs (lamotrigine, carbamazepine, oxcarbazepine, and topiramate)." | 9.41 | Gabapentin monotherapy for epilepsy: A review. ( Abakumova, T; Hoyle, CHV; Ziganshina, LE, 2023) |
| "To evaluate the efficacy and safety of gabapentin (GBP) in idiopathic or crypto/symptomatic partial epilepsy in adults." | 9.12 | [Efficacy, safety and effect on the quality of life of gabapentin in adult epilepsy--results of a prospective open-label quasi naturalistic Hungarian multicenter study (phase human-IV)]. ( Rajna, P; Szíjártó, E, 2006) |
| "To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine (CBZ) in older patients with epilepsy." | 9.11 | New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. ( Boardman, KD; Carter, GS; Collins, JF; Felicetta, J; Frederick, T; Marks, W; Pryor, F; Ramsay, RE; Rowan, AJ; Spitz, M; Tomyanovich, ML; Towne, A; Uthman, BM, 2005) |
| "This randomised, double-blind study compared the newer antiepileptic drugs (AEDs) gabapentin (GBP) and lamotrigine (LTG) as monotherapy in newly diagnosed epilepsy." | 9.10 | Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. ( Anhut, H; Brodie, MJ; Chadwick, DW; Garofalo, EA; Maton, S; Messmer, SL; Murray, G; Otte, A; Sauermann, W, 2002) |
| "A retrospective audit of the perceived efficacy and tolerability of adjunctive gabapentin (GBT) therapy in patients with intractable epilepsy was carried out." | 9.09 | An audit of the perceived efficacy and tolerability of gabapentin therapy in an out-patient cohort with chronic epilepsy. ( Duncan, JS; Langan, Y; Sander, JW, 1999) |
| "To evaluate the efficacy and safety of gabapentin (GBP) in partial epilepsy in children." | 9.09 | Gabapentin in childhood epilepsy: a prospective evaluation of efficacy and safety. ( Boenigk, HE; Borusiak, P; Korn-Merker, E, 2000) |
| "The aim of this study was to evaluate the efficacy and safety of gabapentin in patients with learning disabilities and resistant epilepsy, comparing the effects of gabapentin with lamotrigine on efficacy, behaviour and mood." | 9.09 | A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. ( Brown, S; Crawford, P; Kerr, M, 2001) |
| " Global improvement data from five double-blind clinical trials of gabapentin as add-on therapy in patients with epilepsy were reviewed to assess the effects of gabapentin on mood." | 9.08 | Effect of gabapentin (Neurontin) [corrected] on mood and well-being in patients with epilepsy. ( Dimond, KR; Lamoreaux, L; Pande, AC; Pierce, MW, 1996) |
| "To study the interaction between gabapentin (GBP) and high-protein meals, 12 patients with epilepsy were administered this drug both while in a fasting state and after a high-protein meal." | 9.08 | Oral gabapentin disposition in patients with epilepsy after a high-protein meal. ( Baraldo, M; Benetello, P; Fortunato, M; Furlanut, M; Pea, F; Testa, G; Tognon, A, 1997) |
| "The effect of gabapentin on cognition and quality of life (QoL) in patients with epilepsy was investigated using a controlled pre- and post-treatment design." | 9.08 | Effects of gabapentin on cognition and quality of life in patients with epilepsy. ( Emmers, E; Mortimore, C; Trimble, M, 1998) |
| " Controlled trials in elderly patients with epilepsy demonstrate efficacy and tolerability comparable to gabapentin." | 8.84 | Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. ( Nanry, K; Ramsay, E; Sajatovic, M; Thompson, T, 2007) |
| " However, a MEDLINE search using the search terms gabapentin and epilepsy, spanning back to the year 1986, produced numerous published reports from randomized, placebo-controlled and open-label trials, as well as case reports." | 8.82 | Gabapentin dosing in the treatment of epilepsy. ( Gidal, BE; McLean, MJ, 2003) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 8.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "This study evaluated the effect of androsterone (AND), a metabolite of testosterone, on the ability of selected classical and novel antiepileptic drugs to prevent seizures caused by maximal electroshock (MES), which may serve as an experimental model of human generalized tonic-clonic seizures in mice." | 7.91 | Effects of androsterone on the protective action of various antiepileptic drugs against maximal electroshock-induced seizures in mice. ( Aebisher, D; Bartusik-Aebisher, D; Buszewicz, G; Kołodziejczyk, P; Mróz, K; Mróz, T; Tutka, P; Łuszczki, JJ, 2019) |
| " He had been administered phenytoin and gabapentin for the treatment of symptomatic traumatic epilepsy 8 years before." | 7.88 | Hypothyroidism induced by phenytoin and gabapentin: A Case Report. ( Ishii, K; Miyake, Z; Tamaoka, A, 2018) |
| "To characterize and quantify the variability of serial gabapentin concentrations in elderly patients with epilepsy." | 7.85 | Factors in Variability of Serial Gabapentin Concentrations in Elderly Patients with Epilepsy. ( Birnbaum, AK; Collins, JF; Conway, JM; Eberly, LE; Leppik, IE; Macias, FM; Ramsay, RE, 2017) |
| "These data indicate that MSCs were superior to gabapentin in ameliorating PTZ-induced epileptogenesis and verified the potential use of MSCs in seizure control, motor and cognitive impairments, oxidative stress, and the impairing GABA level in experimentally induced epilepsy." | 7.80 | Effects of intravenous human umbilical cord blood mesenchymal stem cell therapy versus gabapentin in pentylenetetrazole-induced chronic epilepsy in rats. ( Essawy, SS; Ewais, MM; Mohammed, AS; Tawfik, MK, 2014) |
| "To assess whether there is a change in seizure activity in dogs with refractory epilepsy that are receiving appropriate doses of phenobarbitone and/or potassium bromide, when gabapentin is added to the therapeutic regimen." | 7.73 | Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent. ( Govendir, M; Malik, R; Perkins, M, 2005) |
| "The objective of this study was to assess the safety of gabapentin (Neurontin) exposure in human pregnancy." | 7.72 | Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. ( Montouris, G, 2003) |
| "To compare the long-term retention of gabapentin (GBP), lamotrigine (LTG), and vigabatrin (VGB) by patients with chronic epilepsy and the reasons for treatment discontinuation." | 7.70 | The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. ( Chadwick, DW; Fenwick, PB; Mawer, GE; Sander, JW; Wong, IC, 1999) |
| " We reported that daily dosing increased brain gamma-aminobutyric acid (GABA) in patients with epilepsy." | 7.70 | Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients. ( Hyder, F; Mattson, RH; Petroff, OA; Rothman, DL, 2000) |
| "We sought to determine the long-term retention rates of lamotrigine (LTG), gabapentin (GBP), and topiramate (TPM) therapy for patients at a tertiary referral clinic for chronic, refractory epilepsy." | 7.70 | Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. ( Lhatoo, SD; Polizzi, G; Sander, JW; Wong, IC, 2000) |
| "Gabapentin (GBP) is a non-metabolized antiepileptic drug that is eliminated by renal excretion and displays saturable, dose dependent absorption." | 6.69 | Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. ( Bockbrader, HN; DeCerce, J; Gidal, BE; Gonzalez, J; Kruger, S; Pitterle, ME; Ramsay, RE; Rutecki, P, 1998) |
| "Gabapentin is an antiepileptic drug (AED) by design expected to mimic the action of the neurotransmitter gamma-aminobutyric acid (GABA)." | 6.44 | Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy. ( Striano, P; Striano, S, 2008) |
| "Gabapentin is a recently introduced antiepileptic drug for the treatment of partial seizures." | 6.40 | Gabapentin for treatment of epilepsy in children. ( Holmes, GL, 1997) |
| "Gabapentin appears to be a useful new AED." | 6.39 | Gabapentin: a new agent for the management of epilepsy. ( Andrews, CO; Fischer, JH, 1994) |
| "Felbamate was licensed in 1993 for use as adjunctive therapy or monotherapy in adults with partial or tonic-clonic seizures and as adjunctive therapy for children with the Lennox-Gastaut syndrome." | 6.39 | Guidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin. ( Laxer, KD, 1994) |
| "Gabapentin is an antiepileptic drug with an unknown mechanism of action apparently dissimilar to that of other antiepileptic agents, and possessing some desirable pharmacokinetic traits." | 6.38 | Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. ( Goa, KL; Sorkin, EM, 1993) |
| "Gabapentin as monotherapy probably controlled seizures no better and no worse than comparator AEDs (lamotrigine, carbamazepine, oxcarbazepine, and topiramate)." | 5.41 | Gabapentin monotherapy for epilepsy: A review. ( Abakumova, T; Hoyle, CHV; Ziganshina, LE, 2023) |
| " GBP plasma concentrations in the neonates declined with an estimated half-life of 14 h." | 5.33 | Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? ( Ohman, I; Tomson, T; Vitols, S, 2005) |
| "The influence of age and administered daily dosage on the plasma concentrations of gabapentin (GBP) at steady state was evaluated in a group of 41 children and young adults (aged 3-30 years) receiving long-term adjunctive treatment with GBP for the management of refractory partial-onset seizures." | 5.32 | Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. ( Bonanni, P; Bonomi, I; Ferrari, AR; Gatti, G; Guerrini, R; Perucca, E, 2003) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 5.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| "To evaluate the efficacy and safety of gabapentin (GBP) in idiopathic or crypto/symptomatic partial epilepsy in adults." | 5.12 | [Efficacy, safety and effect on the quality of life of gabapentin in adult epilepsy--results of a prospective open-label quasi naturalistic Hungarian multicenter study (phase human-IV)]. ( Rajna, P; Szíjártó, E, 2006) |
| "To compare clinicians' choice of one of the standard epilepsy drug treatments (carbamazepine or valproate) versus appropriate comparator new drugs." | 5.12 | A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. ( Appleton, R; Baker, GA; Chadwick, DW; Doughty, J; Eaton, B; Gamble, C; Jacoby, A; Marson, AG; Shackley, P; Smith, DF; Tudur-Smith, C; Vanoli, A; Williamson, PR, 2007) |
| "To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine (CBZ) in older patients with epilepsy." | 5.11 | New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. ( Boardman, KD; Carter, GS; Collins, JF; Felicetta, J; Frederick, T; Marks, W; Pryor, F; Ramsay, RE; Rowan, AJ; Spitz, M; Tomyanovich, ML; Towne, A; Uthman, BM, 2005) |
| "This randomised, double-blind study compared the newer antiepileptic drugs (AEDs) gabapentin (GBP) and lamotrigine (LTG) as monotherapy in newly diagnosed epilepsy." | 5.10 | Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. ( Anhut, H; Brodie, MJ; Chadwick, DW; Garofalo, EA; Maton, S; Messmer, SL; Murray, G; Otte, A; Sauermann, W, 2002) |
| "The aim of the study was to find out the percentage of patients with localization-related epilepsy achieving complete seizure control with gabapentin (GBP) add-on therapy." | 5.09 | Gabapentin add-on treatment: how many patients become seizure-free? An open-label multicenter study. ( Elger, CE; Mayer, T; Schütte, W; Wolf, P, 1999) |
| "A retrospective audit of the perceived efficacy and tolerability of adjunctive gabapentin (GBT) therapy in patients with intractable epilepsy was carried out." | 5.09 | An audit of the perceived efficacy and tolerability of gabapentin therapy in an out-patient cohort with chronic epilepsy. ( Duncan, JS; Langan, Y; Sander, JW, 1999) |
| "To evaluate the efficacy and safety of gabapentin (GBP) in partial epilepsy in children." | 5.09 | Gabapentin in childhood epilepsy: a prospective evaluation of efficacy and safety. ( Boenigk, HE; Borusiak, P; Korn-Merker, E, 2000) |
| "Our objective was to determine, in three separate studies, the effects of controlled-release carbamazepine (CBZ-CR), lamotrigine (LTG), and gabapentin (GBP) on nocturnal sleep in epilepsy." | 5.09 | Effect of anticonvulsants on nocturnal sleep in epilepsy. ( Diomedi, M; Gigli, GL; Marciani, MG; Placidi, F; Romigi, A; Scalise, A, 2000) |
| "The aim of this study was to evaluate the efficacy and safety of gabapentin in patients with learning disabilities and resistant epilepsy, comparing the effects of gabapentin with lamotrigine on efficacy, behaviour and mood." | 5.09 | A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. ( Brown, S; Crawford, P; Kerr, M, 2001) |
| "Gabapentin was administered in single doses of 10 mg/kg (N=48 healthy subjects, age 1 month-12 years) or in multiple doses of 10-65 mg/kg per day (N=205 patients with epilepsy, age 2 months-13 years) at 08:00, 14:00, and 20:00." | 5.09 | Population pharmacokinetics of gabapentin in infants and children. ( Bockbrader, HN; Garofalo, E; Ouellet, D; Shapiro, DY; Wesche, DL, 2001) |
| " Global improvement data from five double-blind clinical trials of gabapentin as add-on therapy in patients with epilepsy were reviewed to assess the effects of gabapentin on mood." | 5.08 | Effect of gabapentin (Neurontin) [corrected] on mood and well-being in patients with epilepsy. ( Dimond, KR; Lamoreaux, L; Pande, AC; Pierce, MW, 1996) |
| "To study the interaction between gabapentin (GBP) and high-protein meals, 12 patients with epilepsy were administered this drug both while in a fasting state and after a high-protein meal." | 5.08 | Oral gabapentin disposition in patients with epilepsy after a high-protein meal. ( Baraldo, M; Benetello, P; Fortunato, M; Furlanut, M; Pea, F; Testa, G; Tognon, A, 1997) |
| "The effect of gabapentin on cognition and quality of life (QoL) in patients with epilepsy was investigated using a controlled pre- and post-treatment design." | 5.08 | Effects of gabapentin on cognition and quality of life in patients with epilepsy. ( Emmers, E; Mortimore, C; Trimble, M, 1998) |
| "A systematic review of FORCTs and randomised controlled trials (RCT) of topiramate, levetiracetam and gabapentin as adjuvant therapy in refractory adult epilepsy was conducted." | 4.84 | Reporting and analysis of open-label extension studies of anti-epileptic drugs. ( Hemming, K; Hutton, JL; Maguire, MJ; Marson, AG, 2008) |
| " The USA guideline for epilepsy treatment recommends that patients with newly diagnosed epilepsy can be treated with gabapentin, lamotrigine, topiramate, and oxcarbazepine." | 4.84 | [Newer antiepileptic drugs]. ( Matsuura, M, 2007) |
| " Controlled trials in elderly patients with epilepsy demonstrate efficacy and tolerability comparable to gabapentin." | 4.84 | Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. ( Nanry, K; Ramsay, E; Sajatovic, M; Thompson, T, 2007) |
| " Finally, we consider the link between alpha2delta subunits and disease, both in terms of spontaneous and engineered mouse mutants that show cerebellar ataxia and spike-wave epilepsy, and in terms of neuropathic pain and the mechanism of action of the gabapentinoid drugs - small-molecule ligands of the alpha2delta-1 and alpha2delta-2 subunits." | 4.84 | Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. ( Davies, A; Dolphin, AC; Douglas, L; Hendrich, J; Van Minh, AT; Wratten, J, 2007) |
| " However, a MEDLINE search using the search terms gabapentin and epilepsy, spanning back to the year 1986, produced numerous published reports from randomized, placebo-controlled and open-label trials, as well as case reports." | 4.82 | Gabapentin dosing in the treatment of epilepsy. ( Gidal, BE; McLean, MJ, 2003) |
| "The introduction of these new antiepileptic drugs, from felbamate to levetiracetam, raised hope of control of epilepsy with fewer adverse effects and improved quality of life." | 4.81 | New antiepileptic drug therapies. ( Bergin, AM; Connolly, M, 2002) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 4.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "Gabapentin (GBP) is a antiepileptic drug (AED) indicated as adjunct therapy for treatment of partial seizures, with and without secondary generalization, in patients 12 and older with epilepsy." | 4.80 | Gabapentin. ( Morris, GL, 1999) |
| "To evaluate the efficacy and tolerability of the newly developed antiepileptic drugs gabapentin, lamotrigine, tiagabine, topiramate, vigabatrin, and zonisamide in patients with refractory partial epilepsy." | 4.79 | New antiepileptic drugs: a systematic review of their efficacy and tolerability. ( Chadwick, DW; Kadir, ZA; Marson, AG, 1996) |
| "Gabapentin, lamotrigine, tiagabine, topiramate, vigabatrin, and zonisamide are all administered as add-on therapy for treatment of patients with refractory epilepsy." | 4.79 | Clinical administration of new antiepileptic drugs: an overview of safety and efficacy. ( Chadwick, DW; Kadir, Z; Marson, T, 1996) |
| "Since 1994, three new antiepileptic drugs, felbamate, lamotrigene, and gabapentin, have been released for the treatment of epilepsy." | 4.79 | A review of the newer antiepileptic drugs and the ketogenic diet. ( Barron, TF; Hunt, SL, 1997) |
| "Gabapentin (GBP), lamotrigine (LTG), tiagabine (TGB), topiramate (TPM), vigabatrin (VGB), and zonisamide (ZNS) are all in use as "add-on" treatment for patients with refractory epilepsy." | 4.79 | The new antiepileptic drugs: a systematic review of their efficacy and tolerability. ( Chadwick, DW; Hutton, JL; Kadir, ZA; Marson, AG, 1997) |
| " Felbamate (FBM) is effective in the treatment of partial seizures and Lennox-Gastaut epilepsy." | 4.78 | Advances in the pharmacotherapy of epilepsy. ( Ramsay, RE, 1993) |
| " We compared new users of recently approved versus established medications for management of diabetic peripheral neuropathy (pregabalin versus gabapentin), Parkinson disease psychosis (pimavanserin versus quetiapine), and epilepsy (brivaracetam versus levetiracetam)." | 4.31 | Channeling of New Neuropsychiatric Drugs-Impact on Safety and Effectiveness Studies. ( Abraham, DS; Blank, LJ; Gray, SL; Hennessy, S; Leonard, CE; Nguyen, TPP; Thibault, D; Weintraub, D; Willis, AW, 2023) |
| "The present study identifies a significant positive association between ASM and LUTI incidence and antibiotic prescriptions in patients with epilepsy treated with pregabalin, whereas a protective effect was found for carbamazepine in women only." | 4.12 | Association between anti-seizure medication and the risk of lower urinary tract infection in patients with epilepsy. ( Ehrenberg, C; Gremke, N; Kalder, M; Kostev, K; Möller, L; Printz, M, 2022) |
| "This study evaluated the effect of androsterone (AND), a metabolite of testosterone, on the ability of selected classical and novel antiepileptic drugs to prevent seizures caused by maximal electroshock (MES), which may serve as an experimental model of human generalized tonic-clonic seizures in mice." | 3.91 | Effects of androsterone on the protective action of various antiepileptic drugs against maximal electroshock-induced seizures in mice. ( Aebisher, D; Bartusik-Aebisher, D; Buszewicz, G; Kołodziejczyk, P; Mróz, K; Mróz, T; Tutka, P; Łuszczki, JJ, 2019) |
| " He had been administered phenytoin and gabapentin for the treatment of symptomatic traumatic epilepsy 8 years before." | 3.88 | Hypothyroidism induced by phenytoin and gabapentin: A Case Report. ( Ishii, K; Miyake, Z; Tamaoka, A, 2018) |
| "To characterize and quantify the variability of serial gabapentin concentrations in elderly patients with epilepsy." | 3.85 | Factors in Variability of Serial Gabapentin Concentrations in Elderly Patients with Epilepsy. ( Birnbaum, AK; Collins, JF; Conway, JM; Eberly, LE; Leppik, IE; Macias, FM; Ramsay, RE, 2017) |
| "We compared persistence of antiepileptic drugs (AEDs) including carbamazepine, oxcarbazepine, gabapentin, lamotrigine, topiramate, valproic acid, and phenytoin in an Asian population with epilepsy." | 3.83 | Comparative persistence of antiepileptic drugs in patients with epilepsy: A STROBE-compliant retrospective cohort study. ( Hsieh, CY; Huang, CW; Lai, EC; Lin, SJ; Setoguchi, S; Su, CC; Yang, YK, 2016) |
| "Gabapentin and pregabalin are antiepileptic drugs (AEDs) with epilepsy and neuropathic pain indications." | 3.81 | Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. ( Baftiu, A; Beiske, G; Burns, ML; Johannessen Landmark, C; Johannessen, SI, 2015) |
| "These data indicate that MSCs were superior to gabapentin in ameliorating PTZ-induced epileptogenesis and verified the potential use of MSCs in seizure control, motor and cognitive impairments, oxidative stress, and the impairing GABA level in experimentally induced epilepsy." | 3.80 | Effects of intravenous human umbilical cord blood mesenchymal stem cell therapy versus gabapentin in pentylenetetrazole-induced chronic epilepsy in rats. ( Essawy, SS; Ewais, MM; Mohammed, AS; Tawfik, MK, 2014) |
| "In this study of older adults with epilepsy, lamotrigine was the most effective AED as measured by 12-month retention and seizure freedom, with levetiracetam a close second." | 3.76 | Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. ( Arif, H; Bazil, CW; Buchsbaum, R; Hirsch, LJ; Pierro, J; Resor, SR; Sims, J; Whalen, M, 2010) |
| "Our study suggests that there are clinically significant differences among gabapentin, lamotrigine, levetiracetam, tiagabine, and topiramate as treatment for focal epilepsy in everyday practice." | 3.75 | Retention rates of new antiepileptic drugs in localization-related epilepsy: a single-center study. ( Auvinen, A; Fallah, M; Keränen, T; Peltola, J; Peltola, M; Raitanen, J, 2009) |
| "An 8-year-old boy with a neurodegenerative disease of unknown origin and an epilepsy disorder developed an urticarial rash and irritability 10 and 4 days, respectively, after the start of gabapentin 20 mg/kg 3 times a day for epilepsy control." | 3.75 | Probability of rash related to gabapentin therapy in a child. ( de Wildt, SN; Gijsen, VM; Ito, S, 2009) |
| "We investigated efficacy of prolonged intraventricular gabapentin (GBP) infusion in the rat flurothyl epilepsy model." | 3.74 | Intraventricular administration of gabapentin in the rat increases flurothyl seizure threshold. ( Fisher, RS; Kraus, AC; Oommen, J, 2007) |
| "To assess whether there is a change in seizure activity in dogs with refractory epilepsy that are receiving appropriate doses of phenobarbitone and/or potassium bromide, when gabapentin is added to the therapeutic regimen." | 3.73 | Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent. ( Govendir, M; Malik, R; Perkins, M, 2005) |
| "Thirty patients were enrolled: 10 on gabapentin, 10 on lamotrigine and 10 on carbamazepine monotherapy for epilepsy." | 3.73 | Measuring the effects of antiepileptic medications on balance in older people. ( Blum, D; Fife, TD; Fisher, RS, 2006) |
| "The objective of this study was to assess the safety of gabapentin (Neurontin) exposure in human pregnancy." | 3.72 | Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. ( Montouris, G, 2003) |
| " Hence, the standard of care for older patients with epilepsy should be reevaluated, although the vast use of phenytoin in this population suggests that change in practice patterns may be difficult." | 3.72 | Potentially inappropriate antiepileptic drugs for elderly patients with epilepsy. ( Berlowitz, D; Charbonneau, A; Cramer, J; Kazis, L; Knoefel, J; Mandell, A; Pugh, MJ, 2004) |
| "Gabapentin (1-(aminomethyl)cyclohexane acetic acid, CAS 601 42-96-3, GBP, Neurontin) and its derivative gabapentin-lactam (8-aza-spiro[5,4]decan-9-one, GBP-L) were determined by HPLC in the serum of patients with focal epilepsy treated with GBP." | 3.72 | Determination of gabapentin-lactam in serum of patients under gabapentin therapy. ( Feuerstein, TJ; Knörle, R; Schulze-Bonhage, A, 2004) |
| "This postmarketing surveillance study of lamotrigine (LTG) was performed to provide complementary data to large-scale Prescription-Event Monitoring study with a retrospective case records survey in five tertiary referral epilepsy centres in the United Kingdom." | 3.71 | Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom. ( Mawer, GE; Sander, JW; Wong, IC, 2001) |
| " In the last decade, pregnancy registries have been activated by collaborative groups of physicians in Europe (EURAP), North America (NAREP), Australia and India (the latter two recently merged into EURAP), to enroll a large number of exposed women to be monitored prospectively with standardized methods, and by three pharmaceutical companies marketing lamotrigine, gabapentin and vigabatrin, as part of their post-marketing surveillance." | 3.71 | Pregnancy registries in epilepsy. ( Annegers, JF; Beghi, E, 2001) |
| " Gabapentin is a new antiepileptic drug not appreciably metabolized by the liver in humans, and it appears to be safe and effective in the maintenance therapy of epilepsy in these patients." | 3.70 | Treatment of seizures in acute intermittent porphyria: safety and efficacy of gabapentin. ( Brambilla, A; Erli, LC; Grandi, R; Mirabile, D; Zadra, M, 1998) |
| "To compare the long-term retention of gabapentin (GBP), lamotrigine (LTG), and vigabatrin (VGB) by patients with chronic epilepsy and the reasons for treatment discontinuation." | 3.70 | The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. ( Chadwick, DW; Fenwick, PB; Mawer, GE; Sander, JW; Wong, IC, 1999) |
| "To report on the occurrence of myoclonus in patients receiving gabapentin (GBP) for the treatment of epilepsy." | 3.70 | Myoclonus associated with the use of gabapentin. ( Asconapé, J; DellaBadia, J; Diedrich, A, 2000) |
| " We reported that daily dosing increased brain gamma-aminobutyric acid (GABA) in patients with epilepsy." | 3.70 | Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients. ( Hyder, F; Mattson, RH; Petroff, OA; Rothman, DL, 2000) |
| "We sought to determine the long-term retention rates of lamotrigine (LTG), gabapentin (GBP), and topiramate (TPM) therapy for patients at a tertiary referral clinic for chronic, refractory epilepsy." | 3.70 | Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. ( Lhatoo, SD; Polizzi, G; Sander, JW; Wong, IC, 2000) |
| "Gabapentin represents a significant advance in the management of epilepsy." | 3.69 | Gabapentin (NEURONTIN)--a novel anticonvulsant. ( Murdoch, LA, 1994) |
| "We report two cases of unusual movement disorders associated with the use of gabapentin (GBP) in patients being treated for epilepsy who were otherwise neurologically intact." | 3.69 | Movement disorders associated with the use of gabapentin. ( Krahn, LE; Reeves, AL; Sharbrough, FW; So, EL, 1996) |
| "To evaluate the relationship of gabapentin therapy with choreoathetotic movements in mentally retarded patients treated with intractable epilepsy." | 3.69 | Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients. ( Chudnow, RS; Dewey, RB; Lawson, CR, 1997) |
| "Epilepsy is a chronic disease of the central nervous system characterized by recurrent epileptic seizures." | 3.01 | Second Generation of Antiepileptic Drugs and Oxidative Stress. ( Czuczwar, SJ; Kamieniak, M; Kośmider, K; Miziak, B, 2023) |
| "The phenytoin treatment causes cerebellar defect and anemia." | 2.82 | The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches. ( Agrawal, M; Dhurandhar, Y; Panda, SP, 2022) |
| " It has been suggested that this transportation is capacity limited, thus decreasing GBP bioavailability at higher doses." | 2.71 | The absorption of gabapentin following high dose escalation. ( Beran, RG; Berry, DJ; Clarke, LA; Hung, WT; Plunkeft, MJ, 2003) |
| "Gabapentin (GBP) is a non-metabolized antiepileptic drug that is eliminated by renal excretion and displays saturable, dose dependent absorption." | 2.69 | Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. ( Bockbrader, HN; DeCerce, J; Gidal, BE; Gonzalez, J; Kruger, S; Pitterle, ME; Ramsay, RE; Rutecki, P, 1998) |
| " Two analyses of adverse events are presented: tolerability and safety." | 2.69 | Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. ( Bernstein, P; Faught, RE; Holmes, GL; Magnus-Miller, L; McLean, MJ; Morrell, MJ; Privitera, MD; Rose-Legatt, A; Willmore, LJ, 1999) |
| " Furthermore, most preclinical antiepileptogenic studies lack information needed for translation, such as dose-blood level relationship, brain target engagement, and dose-response, and many use treatment parameters that cannot be applied clinically, for example, treatment initiation before or at the time of injury and dosing higher than tolerated human equivalent dosing." | 2.66 | Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? ( Bar-Klein, G; Friedman, A; Hameed, MQ; Jozwiak, S; Kaminski, RM; Klein, P; Klitgaard, H; Koepp, M; Löscher, W; Prince, DA; Rotenberg, A; Twyman, R; Vezzani, A; Wong, M, 2020) |
| "Epilepsy is one of the most common neurological complications in pregnancy; some women continue to use antiepileptic drugs (AEDs) to control seizures." | 2.66 | [Transfer Mechanisms of Compounds between Mother and Fetus/Infant Aimed for Optimized Medication during Pregnancy and Breastfeeding]. ( Furugen, A, 2020) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| "Pediatric epilepsy is a common, chronic, and challenging physical illness for children and their families." | 2.46 | Psychiatric concerns in pediatric epilepsy. ( Bujoreanu, IS; DeMaso, DR; Ibeziako, P, 2010) |
| "Gabapentin is an antiepileptic drug (AED) by design expected to mimic the action of the neurotransmitter gamma-aminobutyric acid (GABA)." | 2.44 | Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy. ( Striano, P; Striano, S, 2008) |
| "A rationale for their use in migraine prophylaxis is the hypothesis that migraine and epilepsy share several common pathogenetic mechanisms." | 2.44 | Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. ( Calabresi, P; Cupini, LM; Galletti, F; Rossi, C; Sarchielli, P, 2007) |
| " Individualization of dosage and avoidance of unnecessary polypharmacy are essential for safe utilization of anti-epileptic drugs." | 2.44 | [Epilepsy in the elderly]. ( Yoshino, A, 2007) |
| " For drugs that are eliminated renally completely unchanged (gabapentin, pregabalin and vigabatrin) or mainly unchanged (levetiracetam and topiramate), the pharmacokinetic variability is less pronounced and more predictable." | 2.43 | Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? ( Johannessen, SI; Tomson, T, 2006) |
| "The pharmacokinetic properties of a drug are the primary deter-minant of the extent and duration of drug action, and influence susceptibility to clinically important drug interactions." | 2.42 | The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ( Johannessen, SI; Perucca, E, 2003) |
| "Many forms of epilepsy are intractable to current therapies and there is a pressing need to develop agents and strategies to not only suppress seizures, but also cure epilepsy." | 2.41 | Ca2+ channels and epilepsy. ( Jones, OT, 2002) |
| "Gabapentin is a drug that shares a similar structure to that of GABA, although its mechanism of action cannot be explained solely by a direct gaba mimetic effect." | 2.41 | [Characteristics and indications of gabapentin]. ( Sancho-Rieger, J, 2002) |
| "Although antiepileptic drugs (AEDs) are commonly used to control and prevent seizures, their long-term use carries a considerable risk of morbidity." | 2.41 | Antiepileptic drug therapy for adults: when to initiate and how to choose. ( Sirven, JI, 2002) |
| " However, on rare occasions, they can progress to more severe cutaneous disorders, including Stevens-Johnson syndrome and toxic epidermal necrolysis." | 2.41 | Therapeutic safety monitoring: what to look for and when to look for it. ( Harden, CL, 2000) |
| "Epilepsy affects 1." | 2.41 | New antiepileptic drugs and preparations. ( Jagoda, A; Yoon, Y, 2000) |
| "Standard antiepileptic drugs (AEDs) have a number of pharmacokinetic shortcomings, and AEDs with more favorable profiles would be preferred." | 2.40 | Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. ( Johannessen, SI, 1997) |
| "Standard antiepileptic drugs (AEDs) are associated with a wide variety of acute and chronic adverse events and with many interactions with each other and with non-AEDs that complicate patient management." | 2.40 | Overview of the safety of newer antiepileptic drugs. ( Shorvon, S; Stefan, H, 1997) |
| "Felbamate, however, has been linked with substantially increased incidence of aplastic anemia, and the other new AEDs have been studied for relatively short periods of time." | 2.40 | Pharmacologic and dietary therapies in epilepsy: conventional treatments and recent advances. ( Chapman, DP; Giles, WH, 1997) |
| "Gabapentin is a recently introduced antiepileptic drug for the treatment of partial seizures." | 2.40 | Gabapentin for treatment of epilepsy in children. ( Holmes, GL, 1997) |
| "Gamma-aminobutyric acid (GABA) plays a pivotal role in suppressing the origin and spread of seizure activity." | 2.40 | Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin. ( Petroff, OA; Rothman, DL, 1998) |
| "Successful treatment of seizure disorders in small animals requires proper patient assessment, understanding the principles of antiepileptic drug (AED) therapy, designing a strategy for pharmacotherapy, and plans for emergency treatment." | 2.40 | Antiepileptic drug therapy. ( Podell, M, 1998) |
| "Gabapentin is an antiepileptic drug used in the treatment of partial and generalized tonic-clonic seizures." | 2.40 | Gabapentin. Antiepileptic mechanism of action. ( Kelly, KM, 1998) |
| " Because dosing is often modest, cost should rarely be the overriding factor in choosing a drug for a patient with newly diagnosed epilepsy in the developed world." | 2.40 | Monostars: an aid to choosing an antiepileptic drug as monotherapy. ( Brodie, MJ, 1999) |
| "Gabapentin has few drug-drug interactions, none of which is clinically limiting." | 2.40 | Gabapentin in the management of convulsive disorders. ( McLean, MJ, 1999) |
| "To most effectively treat children with epilepsy syndromes, further research must be completed to validate the positive effects described in case reports, open-label clinical trials, and early controlled clinical trials." | 2.40 | Managing pediatric epilepsy syndromes with new antiepileptic drugs. ( Pellock, JM, 1999) |
| " For all drugs that are metabolized, half-life is shortened and clearance is increased when patients receive concomitant enzyme-inducing agents such as barbiturates, phenytoin, and carbamazepine." | 2.40 | The clinical pharmacokinetics of the new antiepileptic drugs. ( Perucca, E, 1999) |
| "Gabapentin appears to be a useful new AED." | 2.39 | Gabapentin: a new agent for the management of epilepsy. ( Andrews, CO; Fischer, JH, 1994) |
| "Epilepsy is one of the most common neurological disorders." | 2.39 | Newer antiepileptic drugs. Towards an improved risk-benefit ratio. ( Patsalos, PN; Sander, JW, 1994) |
| "Felbamate was licensed in 1993 for use as adjunctive therapy or monotherapy in adults with partial or tonic-clonic seizures and as adjunctive therapy for children with the Lennox-Gastaut syndrome." | 2.39 | Guidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin. ( Laxer, KD, 1994) |
| "With the introduction of three new anti-epileptic drugs (AEDs) in the UK during the past 4 years as adjunctive add-on therapy, the possibility of AED pharmacokinetic interactions has become a relevant consideration." | 2.39 | Phenobarbitone to gabapentin: a guide to 82 years of anti-epileptic drug pharmacokinetic interactions. ( Patsalos, PN, 1994) |
| "Gabapentin is a new, water-soluble, antiepileptic agent with properties of an amino acid." | 2.39 | Clinical pharmacokinetics of gabapentin. ( McLean, MJ, 1994) |
| "Gabapentin, has shown significant promise in the treatment of patients with refractory partial seizures and secondarily generalized tonic-clonic seizures." | 2.39 | Clinical efficacy and safety of gabapentin. ( Ramsay, RE, 1994) |
| " ZNS daily dosage is 400-600 mg." | 2.39 | Antiepileptic drugs in development: prospects for the near future. ( Leppik, IE, 1994) |
| "Antiepileptic drugs (AEDs) in broad use today have a number of pharmacokinetic liabilities, including a propensity for clinically meaningful drug interactions." | 2.39 | Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. ( Perucca, E, 1996) |
| " However, the pharmacokinetic properties of an AED determine its ease of use, i." | 2.39 | Important pharmacokinetic properties of antiepileptic drugs. ( Bourgeois, BF, 1995) |
| "This article surveys the pharmacokinetic parameters for the new antiepileptic drugs (AEDs): felbamate, gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, and vigabatrin." | 2.39 | Pharmacokinetics of new antiepileptic drugs. ( Gram, L, 1996) |
| "Epilepsy is common in individuals who are mentally retarded and/or otherwise multiply handicapped." | 2.39 | The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps. ( Mattson, RH, 1996) |
| "For many years, the medical treatment of epilepsy was based on the use of the same few drugs, which were chosen according to the seizure type in a fairly standardized manner." | 2.39 | New antiepileptic drugs. ( Bourgeois, BF, 1996) |
| " Specific indications and dosage schedules have been provided." | 2.39 | New antiepileptic drugs. ( Brodie, MJ; Wilson, EA, 1996) |
| "Gabapentin is an antiepileptic drug with an unknown mechanism of action apparently dissimilar to that of other antiepileptic agents, and possessing some desirable pharmacokinetic traits." | 2.38 | Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. ( Goa, KL; Sorkin, EM, 1993) |
| "Epilepsy is a disorder of the central nervous system in which the clinical symptoms are recurrent seizures." | 2.38 | Advances in pharmacotherapy: recent developments in the treatment of epilepsy. ( Graves, NM; Leppik, IE, 1993) |
| "The diagnosis of myoclonus was more difficult than those of epilepsy, because the clarification of pathogenesis and definition of diagnosis was lacked." | 2.38 | [Diagnosis and therapy of epilepsy and myoclonus]. ( Okamoto, Y; Ota, K, 1993) |
| "Comorbid diagnosis of headache predicted use of topiramate and VPA, bipolar disease predicted use of LMT and VPA, pain predicted gabapentin, and schizophrenia was associated with VPAs use." | 1.91 | Prescribing Trends of Antiseizure Drugs in Women Veterans With Epilepsy. ( Amuan, ME; Henion, A; Lopez, MR; Panahi, S; Pugh, MJ; VanCott, AC, 2023) |
| "Gabapentin was the most common second- and third-line ASM." | 1.72 | Antiseizure medication treatment pathways for US Medicare beneficiaries with newly treated epilepsy. ( Burke, JF; Choi, H; Terman, SW; Youngerman, BE, 2022) |
| "Epilepsy is very difficult to treat and often involves the combination of two or more AEDs." | 1.56 | Antiepileptic combination therapy with Stevens-Johnson syndrome and toxic epidermal necrolysis: Analysis of a Japanese pharmacovigilance database. ( Hayashi, T; Noguchi, Y; Tachi, T; Takaoka, M; Teramachi, H, 2020) |
| "The predominant seizure types in NLLOE were focal to bilateral tonic-clonic seizures (30%) as well as focal onset impaired awareness motor seizures (IAMS) (22%) and focal onset impaired awareness nonmotor seizures (IANMS) (22%)." | 1.51 | Nonlesional late-onset epilepsy: Semiology, EEG, cerebrospinal fluid, and seizure outcome characteristics. ( Flöel, A; Hamann, L; Süße, M; von Podewils, F, 2019) |
| "Gabapentin has been increasingly used in various indications in recent years." | 1.51 | Therapeutic drug monitoring of gabapentin in various indications. ( Johannessen Landmark, C; Johannessen, SI; Kinge, E; Larsen Burns, M; Stokke Opdal, M, 2019) |
| "Gabapentin is an anticonvulsant medication with an indication from the US Food and Drug Administration for use in partial onset seizures and postherpetic neuralgia in the United States." | 1.51 | A Call for Caution in Prescribing Gabapentin to Individuals With Concurrent Polysubstance Abuse: A Case Report. ( Hasan, S; Martinez, GM; Olabisi, J; Ruekert, L, 2019) |
| "Levetiracetam treatment did not affect bone strength, bone mass, and bone turnover." | 1.46 | Effects of the Antiepileptic Drugs Phenytoin, Gabapentin, and Levetiracetam on Bone Strength, Bone Mass, and Bone Turnover in Rats. ( Izumo, N; Kanda, J; Kobayashi, Y; Onodera, K; Shimakura, T; Takahashi, HE; Wakabayashi, H; Yamamoto, N, 2017) |
| "CNS inflammation is characterized by a disturbance of glial cell functions." | 1.40 | Glia and epilepsy: experimental investigation of antiepileptic drugs in an astroglia/microglia co-culture model of inflammation. ( Dambach, H; Faustmann, PM; Haase, CG; Hinkerohe, D; Hufnagel, A; Moinfar, Z; Prochnow, N; Stienen, MN, 2014) |
| "Gabapentin has been shown to disrupt the interaction of thrombospondin (TSP) with α2δ-1, an auxiliary calcium channel subunit." | 1.40 | Gabapentin attenuates hyperexcitability in the freeze-lesion model of developmental cortical malformation. ( Andresen, L; Dulla, CG; Hampton, D; Maguire, J; Morel, L; Taylor-Weiner, A; Yang, Y, 2014) |
| "Early treatment of epilepsy is warranted to avoid possible severe consequences." | 1.39 | Epilepsy and brain injury: a case report of a dramatic neuropsychiatric vicious circle. ( Angeletti, G; Carbonetti, P; Del Casale, A; Fensore, C; Ferracuti, S; Girardi, P; Kotzalidis, GD; Lazanio, S; Muzi, A; Rapinesi, C; Savoja, V; Scatena, P; Serata, D; Tatarelli, R, 2013) |
| "Gabapentin (GAB) is a newer second-line antiepileptic drug (AED) used in children." | 1.38 | Retention rate of Gabapentin in children with intractable epilepsies at 1 year. ( Ali, I; Gupta, R; Lewis, TG; Mills, JK; Mordekar, SR; Mughal, K; Ruslan, NE; Sasidharan, L; Sharma, R; Siddiqua, A; Ugar, A; Wassmer, E; Whitehouse, WP, 2012) |
| "Current drugs for the treatment of seizure disorders, although effective in many patients, still suffer from a number of failures and are not effective in some forms of resistant epilepsies." | 1.36 | Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain. ( Amato, GS; Burns, JF; Eargle, CW; Fritch, PC; Harrison, W; Jones, L; McNaughton-Smith, G; Roeloffs, R; Wickenden, AD, 2010) |
| " GBP plasma concentrations in the neonates declined with an estimated half-life of 14 h." | 1.33 | Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? ( Ohman, I; Tomson, T; Vitols, S, 2005) |
| "The influence of age and administered daily dosage on the plasma concentrations of gabapentin (GBP) at steady state was evaluated in a group of 41 children and young adults (aged 3-30 years) receiving long-term adjunctive treatment with GBP for the management of refractory partial-onset seizures." | 1.32 | Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. ( Bonanni, P; Bonomi, I; Ferrari, AR; Gatti, G; Guerrini, R; Perucca, E, 2003) |
| "Gabapentin is a clinically effective anticonvulsant with an unclear mechanism of action." | 1.32 | Gabapentin actions on Kir3 currents and N-type Ca2+ channels via GABAB receptors in hippocampal pyramidal cells. ( Bertrand, S; Lacaille, JC; Morin, F; Nagy, F; Nouel, D, 2003) |
| "ent/ent mice develop ataxia by postnatal day 13-15, followed by paroxysmal dyskinesia a few days later." | 1.32 | entla, a novel epileptic and ataxic Cacna2d2 mutant of the mouse. ( Becker, CM; Becker, K; Boison, D; Brill, J; Gouder, N; Hofmann, F; Klocke, R; Klugbauer, N; Paul, D, 2004) |
| "Electroconvulsions were produced by means of an alternating current (ear-clip electrodes, 0." | 1.31 | Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis. ( Borowicz, KK; Czuczwar, SJ; Luszczki, J; Swiader, M, 2002) |
| "Gabapentin (GBP) is a novel antiepileptic drug (AED), currently used as add-on therapy in patients with partial seizures." | 1.31 | Gabapentin-induced modulation of interictal epileptiform activity related to different vigilance levels. ( Bassetti, MA; Marciani, MG; Mattia, D; Placidi, F; Romigi, A; Spanedda, F, 2000) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 1.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| "Lamotrigine was the only drug which antagonized tonic convulsions in the MES test (ED50 = 36 mumol/kg)." | 1.30 | Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. ( Dalby, NO; Nielsen, EB, 1997) |
| "Gabapentin is a new antiepileptic drug." | 1.30 | [Gabapentin--a new antiepileptic agent]. ( Johannessen, SI; Nakken, KO; Rytter, E, 1998) |
| " However, GBP concentrations were much lower after rectal administration; therefore, we concluded that the aqueous solution was poorly absorbed rectally." | 1.30 | Failure of absorption of gabapentin after rectal administration. ( Birnbaum, AK; Caruso, KJ; Cloyd, JC; Jones Saete, C; Kriel, RL; Ricker, BJ, 1997) |
| "Length of seizure disorder, seizure frequency at initiation, the number of previously used failed drugs and the total number of drugs previously used were all significantly lower in the seizure-free group." | 1.30 | The outcome of prescribing novel anticonvulsants in an outpatient setting: factors affecting response to medication. ( Kerr, MP; Thijs, RD, 1998) |
| "In 1993, 27% of patients were being treated for epilepsy and in 1995/6, 30." | 1.30 | The management of epilepsy in a hospital for people with a learning disability. ( Carvill, S; Cassidy, G; Clarke, D, 1999) |
| "Gabapentin is a new AED not appreciably metabolized by the liver in humans." | 1.29 | Gabapentin treatment of seizures in acute intermittent porphyria. ( Tatum, WO; Zachariah, SB, 1995) |
| "Gabapentin is a gamma-aminobutyric acid (GABA) analog which passes the blood-brain barrier." | 1.29 | [New medical treatment of epilepsy]. ( Loiseau, P, 1996) |
| "Gabapentin is a novel antiepileptic drug that has recently been introduced in Canada." | 1.29 | Gabapentin. ( Bruni, J, 1996) |
| "Gabapentin is a novel anti-epileptic drug which enhances GABA (gamma-aminobutyric acid) turnover in certain brain regions, including substantia nigra." | 1.29 | The anticonvulsant gabapentin decreases firing rates of substantia nigra pars reticulata neurons. ( Bloms-Funke, P; Löscher, W, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.77) | 18.7374 |
| 1990's | 122 (46.74) | 18.2507 |
| 2000's | 82 (31.42) | 29.6817 |
| 2010's | 39 (14.94) | 24.3611 |
| 2020's | 16 (6.13) | 2.80 |
| Authors | Studies |
|---|---|
| Fritch, PC | 1 |
| McNaughton-Smith, G | 1 |
| Amato, GS | 1 |
| Burns, JF | 1 |
| Eargle, CW | 1 |
| Roeloffs, R | 1 |
| Harrison, W | 1 |
| Jones, L | 1 |
| Wickenden, AD | 1 |
| McComsey, DF | 1 |
| Smith-Swintosky, VL | 1 |
| Parker, MH | 1 |
| Brenneman, DE | 1 |
| Malatynska, E | 1 |
| White, HS | 1 |
| Klein, BD | 1 |
| Wilcox, KS | 1 |
| Milewski, ME | 1 |
| Herb, M | 1 |
| Finley, MF | 1 |
| Liu, Y | 1 |
| Lubin, ML | 1 |
| Qin, N | 1 |
| Reitz, AB | 1 |
| Maryanoff, BE | 1 |
| Terman, SW | 1 |
| Youngerman, BE | 1 |
| Choi, H | 1 |
| Burke, JF | 1 |
| Panda, SP | 1 |
| Dhurandhar, Y | 1 |
| Agrawal, M | 1 |
| Gremke, N | 1 |
| Printz, M | 1 |
| Möller, L | 1 |
| Ehrenberg, C | 1 |
| Kostev, K | 2 |
| Kalder, M | 1 |
| Tomson, T | 3 |
| Battino, D | 1 |
| Bromley, R | 1 |
| Kochen, S | 2 |
| Meador, KJ | 2 |
| Pennell, PB | 1 |
| Thomas, SV | 1 |
| Hessenberger, M | 1 |
| Haddad, S | 1 |
| Obermair, GJ | 1 |
| Kośmider, K | 1 |
| Kamieniak, M | 1 |
| Czuczwar, SJ | 3 |
| Miziak, B | 1 |
| Abraham, DS | 1 |
| Nguyen, TPP | 1 |
| Blank, LJ | 2 |
| Thibault, D | 1 |
| Gray, SL | 1 |
| Hennessy, S | 1 |
| Leonard, CE | 1 |
| Weintraub, D | 1 |
| Willis, AW | 1 |
| Agarwal, P | 1 |
| Kwon, CS | 1 |
| Jetté, N | 1 |
| Zhao, K | 1 |
| Bai, X | 1 |
| Wang, X | 1 |
| Cao, Y | 1 |
| Zhang, L | 1 |
| Li, W | 1 |
| Wang, S | 1 |
| Lopez, MR | 1 |
| VanCott, AC | 1 |
| Amuan, ME | 1 |
| Panahi, S | 1 |
| Henion, A | 1 |
| Pugh, MJ | 2 |
| Ziganshina, LE | 1 |
| Abakumova, T | 1 |
| Hoyle, CHV | 1 |
| Lawal, OD | 1 |
| Hume, AL | 1 |
| Wen, X | 1 |
| Lattanzi, S | 1 |
| Trinka, E | 1 |
| Del Giovane, C | 1 |
| Nardone, R | 1 |
| Silvestrini, M | 1 |
| Brigo, F | 1 |
| Klein, P | 1 |
| Friedman, A | 1 |
| Hameed, MQ | 1 |
| Kaminski, RM | 1 |
| Bar-Klein, G | 1 |
| Klitgaard, H | 1 |
| Koepp, M | 1 |
| Jozwiak, S | 1 |
| Prince, DA | 1 |
| Rotenberg, A | 1 |
| Twyman, R | 1 |
| Vezzani, A | 1 |
| Wong, M | 1 |
| Löscher, W | 2 |
| Noguchi, Y | 1 |
| Takaoka, M | 1 |
| Hayashi, T | 1 |
| Tachi, T | 1 |
| Teramachi, H | 1 |
| Soldovieri, MV | 1 |
| Freri, E | 1 |
| Ambrosino, P | 1 |
| Rivolta, I | 1 |
| Mosca, I | 1 |
| Binda, A | 1 |
| Murano, C | 1 |
| Ragona, F | 1 |
| Canafoglia, L | 1 |
| Vannicola, C | 1 |
| Solazzi, R | 1 |
| Granata, T | 1 |
| Castellotti, B | 1 |
| Messina, G | 1 |
| Gellera, C | 1 |
| Labalme, A | 1 |
| Lesca, G | 1 |
| DiFrancesco, JC | 1 |
| Taglialatela, M | 1 |
| Furugen, A | 1 |
| Jacob, L | 1 |
| Hamer, HM | 1 |
| Nevitt, SJ | 2 |
| Sudell, M | 2 |
| Weston, J | 2 |
| Tudur Smith, C | 2 |
| Marson, AG | 6 |
| Conway, JM | 1 |
| Eberly, LE | 1 |
| Collins, JF | 2 |
| Macias, FM | 1 |
| Ramsay, RE | 6 |
| Leppik, IE | 3 |
| Birnbaum, AK | 2 |
| Kanda, J | 1 |
| Izumo, N | 1 |
| Kobayashi, Y | 1 |
| Onodera, K | 1 |
| Shimakura, T | 1 |
| Yamamoto, N | 1 |
| Takahashi, HE | 1 |
| Wakabayashi, H | 1 |
| Brandt, C | 1 |
| May, TW | 1 |
| Süße, M | 1 |
| Hamann, L | 1 |
| Flöel, A | 1 |
| von Podewils, F | 1 |
| Tutka, P | 1 |
| Mróz, K | 1 |
| Mróz, T | 1 |
| Buszewicz, G | 1 |
| Aebisher, D | 1 |
| Bartusik-Aebisher, D | 1 |
| Kołodziejczyk, P | 1 |
| Łuszczki, JJ | 1 |
| Miyake, Z | 1 |
| Ishii, K | 1 |
| Tamaoka, A | 1 |
| Larsen Burns, M | 1 |
| Kinge, E | 1 |
| Stokke Opdal, M | 1 |
| Johannessen, SI | 6 |
| Johannessen Landmark, C | 2 |
| Ayala-Guerrero, F | 1 |
| Mexicano, G | 1 |
| Gutiérrez-Chávez, CA | 1 |
| Lazo, LA | 1 |
| Mateos, EL | 1 |
| Laghari, AA | 1 |
| Ahmed, SI | 1 |
| Qadeer, N | 1 |
| Shamim, MS | 1 |
| Martinez, GM | 1 |
| Olabisi, J | 1 |
| Ruekert, L | 1 |
| Hasan, S | 1 |
| Daugaard, CA | 1 |
| Sun, Y | 1 |
| Dreier, JW | 1 |
| Christensen, J | 1 |
| Di Fabio, R | 1 |
| D'Agostino, C | 1 |
| Baldi, G | 1 |
| Pierelli, F | 1 |
| Rapinesi, C | 1 |
| Del Casale, A | 1 |
| Serata, D | 1 |
| Kotzalidis, GD | 1 |
| Scatena, P | 1 |
| Muzi, A | 1 |
| Lazanio, S | 1 |
| Savoja, V | 1 |
| Carbonetti, P | 1 |
| Fensore, C | 1 |
| Ferracuti, S | 1 |
| Angeletti, G | 1 |
| Tatarelli, R | 1 |
| Girardi, P | 1 |
| Dambach, H | 1 |
| Hinkerohe, D | 1 |
| Prochnow, N | 1 |
| Stienen, MN | 1 |
| Moinfar, Z | 1 |
| Haase, CG | 1 |
| Hufnagel, A | 1 |
| Faustmann, PM | 1 |
| Ito, S | 2 |
| Oguni, H | 1 |
| Ohtsuka, Y | 1 |
| Andresen, L | 1 |
| Hampton, D | 1 |
| Taylor-Weiner, A | 1 |
| Morel, L | 1 |
| Yang, Y | 1 |
| Maguire, J | 1 |
| Dulla, CG | 1 |
| Mohammed, AS | 1 |
| Ewais, MM | 1 |
| Tawfik, MK | 1 |
| Essawy, SS | 1 |
| Beiske, G | 1 |
| Baftiu, A | 1 |
| Burns, ML | 1 |
| Vanya, M | 1 |
| Devosa, I | 1 |
| Szok, D | 1 |
| Bártfai, G | 1 |
| Lai, EC | 1 |
| Hsieh, CY | 1 |
| Su, CC | 1 |
| Yang, YK | 1 |
| Huang, CW | 1 |
| Lin, SJ | 1 |
| Setoguchi, S | 1 |
| Maguire, MJ | 1 |
| Hemming, K | 1 |
| Hutton, JL | 2 |
| Striano, P | 1 |
| Striano, S | 1 |
| Peltola, J | 1 |
| Peltola, M | 1 |
| Auvinen, A | 1 |
| Raitanen, J | 1 |
| Fallah, M | 1 |
| Keränen, T | 1 |
| Carpay, JA | 1 |
| Aalbers, K | 1 |
| Graveland, GA | 1 |
| Engelsman, M | 1 |
| Gijsen, VM | 1 |
| de Wildt, SN | 1 |
| Rouvel-Tallec, A | 1 |
| Pellock, JM | 7 |
| Blake, MG | 1 |
| Boccia, MM | 2 |
| Carcaboso, AM | 1 |
| Chiappetta, DA | 1 |
| Höcht, C | 1 |
| Krawczyk, MC | 1 |
| Sosnik, A | 1 |
| Baratti, CM | 2 |
| Cavanna, AE | 1 |
| Ali, F | 1 |
| Rickards, HE | 1 |
| McCorry, D | 1 |
| Arif, H | 1 |
| Buchsbaum, R | 1 |
| Pierro, J | 1 |
| Whalen, M | 1 |
| Sims, J | 1 |
| Resor, SR | 1 |
| Bazil, CW | 2 |
| Hirsch, LJ | 1 |
| Bujoreanu, IS | 1 |
| Ibeziako, P | 1 |
| DeMaso, DR | 1 |
| Lucey, BP | 1 |
| Noetzel, MJ | 1 |
| Duntley, SP | 1 |
| Bittner, S | 1 |
| Höhn, K | 1 |
| Göbel, K | 1 |
| Kleinschnitz, C | 1 |
| Wiendl, H | 1 |
| Meuth, SG | 1 |
| Akamatsu, N | 1 |
| Kaufman, KR | 1 |
| Struck, PJ | 1 |
| Wu, B | 1 |
| Wong, S | 1 |
| Mills, JK | 1 |
| Ruslan, NE | 1 |
| Lewis, TG | 1 |
| Mughal, K | 1 |
| Ali, I | 1 |
| Ugar, A | 1 |
| Wassmer, E | 1 |
| Siddiqua, A | 1 |
| Gupta, R | 1 |
| Mordekar, SR | 1 |
| Sharma, R | 1 |
| Sasidharan, L | 1 |
| Whitehouse, WP | 1 |
| Delattre, M | 1 |
| Savic, RM | 1 |
| Miller, R | 1 |
| Karlsson, MO | 1 |
| Lavielle, M | 1 |
| Tupal, S | 1 |
| Faingold, CL | 1 |
| Terada, K | 1 |
| Inoue, Y | 1 |
| Arvio, M | 1 |
| Sipilä, I | 1 |
| Jones, OT | 1 |
| Borowicz, KK | 1 |
| Swiader, M | 1 |
| Luszczki, J | 1 |
| Wilton, LV | 1 |
| Shakir, S | 1 |
| Brodie, MJ | 4 |
| Chadwick, DW | 7 |
| Anhut, H | 1 |
| Otte, A | 1 |
| Messmer, SL | 1 |
| Maton, S | 2 |
| Sauermann, W | 1 |
| Murray, G | 2 |
| Garofalo, EA | 1 |
| Vega-Hernández, A | 1 |
| Felix, R | 1 |
| Sancho-Rieger, J | 1 |
| Guéguen, A | 1 |
| Guy, C | 1 |
| Cartry, O | 1 |
| Bouchou, K | 1 |
| Gouilloud, S | 1 |
| Cathébras, P | 1 |
| Zachariae, CO | 1 |
| Sirven, JI | 1 |
| Berry, DJ | 1 |
| Beran, RG | 1 |
| Plunkeft, MJ | 1 |
| Clarke, LA | 1 |
| Hung, WT | 1 |
| Gatti, G | 1 |
| Ferrari, AR | 1 |
| Guerrini, R | 1 |
| Bonanni, P | 1 |
| Bonomi, I | 1 |
| Perucca, E | 4 |
| Bergin, AM | 1 |
| Connolly, M | 1 |
| Montouris, G | 2 |
| McLean, MJ | 5 |
| Gidal, BE | 2 |
| Btaiche, IF | 1 |
| Woster, PS | 1 |
| Bertrand, S | 1 |
| Nouel, D | 1 |
| Morin, F | 1 |
| Nagy, F | 1 |
| Lacaille, JC | 1 |
| Huber, B | 1 |
| Tomka-Hoffmeister, M | 1 |
| Brill, J | 1 |
| Klocke, R | 1 |
| Paul, D | 1 |
| Boison, D | 1 |
| Gouder, N | 1 |
| Klugbauer, N | 1 |
| Hofmann, F | 1 |
| Becker, CM | 1 |
| Becker, K | 1 |
| Cramer, J | 1 |
| Knoefel, J | 1 |
| Charbonneau, A | 1 |
| Mandell, A | 1 |
| Kazis, L | 1 |
| Berlowitz, D | 1 |
| Wu, SP | 1 |
| Shyu, MK | 1 |
| Liou, HH | 1 |
| Gau, CS | 1 |
| Lin, CJ | 1 |
| French, JA | 2 |
| Kanner, AM | 1 |
| Bautista, J | 1 |
| Abou-Khalil, B | 1 |
| Browne, T | 1 |
| Harden, CL | 2 |
| Theodore, WH | 1 |
| Bazil, C | 1 |
| Stern, J | 1 |
| Schachter, SC | 1 |
| Bergen, D | 2 |
| Hirtz, D | 1 |
| Montouris, GD | 1 |
| Nespeca, M | 1 |
| Gidal, B | 1 |
| Marks, WJ | 1 |
| Turk, WR | 1 |
| Fischer, JH | 2 |
| Bourgeois, B | 1 |
| Wilner, A | 1 |
| Faught, RE | 2 |
| Sachdeo, RC | 1 |
| Beydoun, A | 1 |
| Glauser, TA | 1 |
| Knörle, R | 1 |
| Feuerstein, TJ | 2 |
| Schulze-Bonhage, A | 1 |
| Marshall, L | 1 |
| Doyle, KM | 1 |
| Kirby, BP | 1 |
| Murphy, D | 1 |
| Shaw, GG | 1 |
| Rowan, AJ | 1 |
| Pryor, F | 1 |
| Boardman, KD | 1 |
| Uthman, BM | 1 |
| Spitz, M | 1 |
| Frederick, T | 1 |
| Towne, A | 1 |
| Carter, GS | 1 |
| Marks, W | 1 |
| Felicetta, J | 1 |
| Tomyanovich, ML | 1 |
| Selai, CE | 2 |
| Trimble, MR | 3 |
| Price, MJ | 1 |
| Remak, E | 1 |
| Harrison, PK | 1 |
| Sheridan, RD | 1 |
| Green, AC | 1 |
| Tattersall, JE | 1 |
| Ohman, I | 1 |
| Vitols, S | 1 |
| Sander, JW | 6 |
| Govendir, M | 1 |
| Perkins, M | 1 |
| Malik, R | 1 |
| Freiman, TM | 1 |
| Surges, R | 1 |
| Kukolja, J | 1 |
| Heinemeyer, J | 1 |
| Klar, M | 1 |
| van Velthoven, V | 1 |
| Zentner, J | 1 |
| Fife, TD | 1 |
| Blum, D | 1 |
| Fisher, RS | 2 |
| Bialer, M | 1 |
| Stefan, H | 3 |
| Rajna, P | 1 |
| Szíjártó, E | 1 |
| Matsuura, M | 1 |
| Sajatovic, M | 1 |
| Ramsay, E | 1 |
| Nanry, K | 1 |
| Thompson, T | 1 |
| Calabresi, P | 1 |
| Galletti, F | 1 |
| Rossi, C | 1 |
| Sarchielli, P | 1 |
| Cupini, LM | 1 |
| Oommen, J | 1 |
| Kraus, AC | 1 |
| Yoshino, A | 1 |
| Davies, A | 1 |
| Hendrich, J | 1 |
| Van Minh, AT | 1 |
| Wratten, J | 1 |
| Douglas, L | 1 |
| Dolphin, AC | 1 |
| Savica, R | 1 |
| Beghi, E | 2 |
| Mazzaglia, G | 1 |
| Innocenti, F | 1 |
| Brignoli, O | 1 |
| Cricelli, C | 1 |
| Caputi, AP | 1 |
| Musolino, R | 1 |
| Spina, E | 1 |
| Trifirò, G | 1 |
| Appleton, R | 3 |
| Baker, GA | 1 |
| Doughty, J | 1 |
| Eaton, B | 1 |
| Gamble, C | 1 |
| Jacoby, A | 1 |
| Shackley, P | 1 |
| Smith, DF | 1 |
| Tudur-Smith, C | 1 |
| Vanoli, A | 1 |
| Williamson, PR | 1 |
| Macleod, S | 1 |
| Appleton, RE | 2 |
| Baillieux, H | 1 |
| Verslegers, W | 1 |
| Paquier, P | 1 |
| De Deyn, PP | 1 |
| Mariën, P | 1 |
| Hwang, H | 1 |
| Kim, KJ | 1 |
| Despland, PA | 3 |
| Macdonald, RL | 2 |
| Kelly, KM | 3 |
| Kilpatrick, C | 1 |
| Kupecz, D | 1 |
| Goa, KL | 1 |
| Sorkin, EM | 1 |
| Murdoch, LA | 1 |
| Pimentel, J | 1 |
| Pinto, F | 1 |
| Tatum, WO | 1 |
| Zachariah, SB | 1 |
| Betts, T | 1 |
| O'Neill, BA | 1 |
| Bloom, DS | 1 |
| Leach, JP | 1 |
| Devinsky, O | 1 |
| Vazquez, B | 1 |
| Luciano, D | 1 |
| Andrews, CO | 1 |
| Chadwick, D | 3 |
| Patsalos, PN | 2 |
| Sivenius, J | 1 |
| Ylinen, A | 1 |
| Kälviäinen, R | 1 |
| Riekkinen, PJ | 1 |
| Buchanan, N | 1 |
| Laxer, KD | 1 |
| Parks, BR | 1 |
| Dostrow, VG | 1 |
| Noble, SL | 1 |
| Byers, VL | 1 |
| Graves, NM | 1 |
| Skolnick, AA | 1 |
| Manack, L | 1 |
| Slater, JD | 1 |
| Okamoto, Y | 1 |
| Ota, K | 1 |
| Galdames, D | 1 |
| Aguilera, L | 1 |
| Fauré, E | 1 |
| Lee, EK | 1 |
| Vassella, F | 2 |
| Krämer, G | 1 |
| Wieser, HG | 1 |
| Lee, DO | 1 |
| Steingard, RJ | 1 |
| Cesena, M | 1 |
| Helmers, SL | 1 |
| Riviello, JJ | 1 |
| Mikati, MA | 1 |
| Vossler, DG | 2 |
| Reynolds, NC | 1 |
| Legido, A | 1 |
| Iivanainen, M | 1 |
| Gaily, E | 1 |
| Loiseau, P | 1 |
| Davies, JA | 1 |
| Dimond, KR | 1 |
| Pande, AC | 1 |
| Lamoreaux, L | 2 |
| Pierce, MW | 1 |
| McDonnell, GV | 1 |
| Morrow, JI | 1 |
| Bourgeois, BF | 3 |
| Reeves, AL | 1 |
| So, EL | 1 |
| Sharbrough, FW | 1 |
| Krahn, LE | 1 |
| Hauck, A | 1 |
| Bhaumik, S | 2 |
| Hussein, G | 1 |
| Troupin, AS | 1 |
| Morton, LD | 2 |
| Jackson, D | 1 |
| Duthie, T | 1 |
| Kadir, ZA | 2 |
| Gram, L | 1 |
| Meldrum, BS | 1 |
| Mattson, RH | 3 |
| Marson, T | 1 |
| Kadir, Z | 1 |
| Bruni, J | 1 |
| Herranz, JL | 2 |
| Grippo, J | 1 |
| Bloms-Funke, P | 1 |
| Morris, HH | 1 |
| Wilson, EA | 1 |
| Shorvon, S | 1 |
| Bannister, SM | 1 |
| Padró, L | 1 |
| Arbizu, T | 1 |
| Rovira, R | 1 |
| Gil-Nagel, A | 1 |
| Gapany, S | 1 |
| Blesi, K | 1 |
| Villanueva, N | 1 |
| Branford, D | 1 |
| Duggirala, C | 1 |
| Ismail, IA | 1 |
| Chapman, DP | 1 |
| Giles, WH | 1 |
| Chudnow, RS | 1 |
| Dewey, RB | 1 |
| Lawson, CR | 1 |
| Wyler, AR | 1 |
| Dalby, NO | 1 |
| Nielsen, EB | 1 |
| Barron, TF | 1 |
| Hunt, SL | 1 |
| Holmes, GL | 2 |
| Pedley, TA | 1 |
| Nakken, KO | 1 |
| Rytter, E | 1 |
| Petroff, OA | 2 |
| Rothman, DL | 2 |
| Kriel, RL | 1 |
| Cloyd, JC | 1 |
| Ricker, BJ | 1 |
| Jones Saete, C | 1 |
| Caruso, KJ | 1 |
| Benetello, P | 1 |
| Furlanut, M | 1 |
| Fortunato, M | 1 |
| Baraldo, M | 1 |
| Pea, F | 1 |
| Tognon, A | 1 |
| Testa, G | 1 |
| Bryans, JS | 1 |
| Davies, N | 1 |
| Gee, NS | 1 |
| Dissanayake, VU | 1 |
| Ratcliffe, GS | 1 |
| Horwell, DC | 1 |
| Kneen, CO | 1 |
| Morrell, AI | 1 |
| Oles, RJ | 1 |
| O'Toole, JC | 1 |
| Perkins, GM | 1 |
| Singh, L | 1 |
| Suman-Chauhan, N | 1 |
| O'Neill, JA | 1 |
| Lücke, A | 1 |
| Musshoff, U | 1 |
| Köhling, R | 1 |
| Osterfeld, M | 1 |
| Mayer, T | 2 |
| Wolf, P | 2 |
| Schütte, W | 2 |
| Speckmann, EJ | 1 |
| DeCerce, J | 1 |
| Bockbrader, HN | 2 |
| Gonzalez, J | 1 |
| Kruger, S | 1 |
| Pitterle, ME | 1 |
| Rutecki, P | 1 |
| Podell, M | 1 |
| Ferrier, IN | 1 |
| Mortimore, C | 1 |
| Trimble, M | 1 |
| Emmers, E | 1 |
| Thijs, RD | 1 |
| Kerr, MP | 1 |
| Zadra, M | 1 |
| Grandi, R | 1 |
| Erli, LC | 1 |
| Mirabile, D | 1 |
| Brambilla, A | 1 |
| Feely, M | 1 |
| Wilner, AN | 1 |
| Elger, CE | 2 |
| Langan, Y | 1 |
| Duncan, JS | 1 |
| Carvill, S | 1 |
| Clarke, D | 1 |
| Cassidy, G | 1 |
| Cramer, JA | 1 |
| Fisher, R | 1 |
| Ben-Menachem, E | 1 |
| French, J | 1 |
| Morrell, MJ | 1 |
| Willmore, LJ | 1 |
| Privitera, MD | 1 |
| Magnus-Miller, L | 1 |
| Bernstein, P | 1 |
| Rose-Legatt, A | 1 |
| Bernatik, J | 1 |
| Knorr, J | 1 |
| Wong, IC | 3 |
| Fenwick, PB | 1 |
| Mawer, GE | 2 |
| Fernández, G | 1 |
| Morris, GL | 1 |
| Korn-Merker, E | 1 |
| Borusiak, P | 1 |
| Boenigk, HE | 1 |
| Datta, PK | 1 |
| Crawford, PM | 1 |
| Acosta, GB | 1 |
| Usiskin, SI | 1 |
| Nicolson, R | 1 |
| Lenane, M | 1 |
| Rapoport, JL | 1 |
| Placidi, F | 2 |
| Diomedi, M | 1 |
| Scalise, A | 1 |
| Marciani, MG | 2 |
| Romigi, A | 2 |
| Gigli, GL | 1 |
| Asconapé, J | 1 |
| Diedrich, A | 1 |
| DellaBadia, J | 1 |
| Hyder, F | 1 |
| Vajda, FJ | 1 |
| Mattia, D | 1 |
| Bassetti, MA | 1 |
| Spanedda, F | 1 |
| Foletti, GB | 1 |
| Lhatoo, SD | 1 |
| Polizzi, G | 1 |
| Yoon, Y | 1 |
| Jagoda, A | 1 |
| Fichtner, K | 1 |
| Alexander, J | 1 |
| Garofalo, E | 2 |
| Crawford, P | 2 |
| Brown, S | 1 |
| Kerr, M | 1 |
| Aldenkamp, AP | 1 |
| Goldberg, JF | 1 |
| Burdick, KE | 1 |
| Bassilios, N | 1 |
| Launay-Vacher, V | 1 |
| Khoury, N | 1 |
| Rondeau, E | 1 |
| Deray, G | 1 |
| Sraer, JD | 1 |
| Ouellet, D | 1 |
| Wesche, DL | 1 |
| Shapiro, DY | 1 |
| Annegers, JF | 1 |
| Hurley, SC | 1 |
| Salinsky, MC | 1 |
| Binder, LM | 1 |
| Oken, BS | 1 |
| Storzbach, D | 1 |
| Aron, CR | 1 |
| Dodrill, CB | 1 |
| Sussman, N | 1 |
| Grant, AC | 1 |
| Oh, H | 1 |
| Foot, M | 1 |
| Wallace, J | 1 |
| Kondo, T | 1 |
| Fromm, GH | 1 |
| Schmidt, B | 1 |
| Porter, RJ | 1 |
| Ghadiali, E | 1 |
| Lane, R | 1 |
| Blumhardt, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Retrospective Study to Evaluate Retention Rate of Topiramate With That of Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment[NCT02098941] | 2,500 participants (Anticipated) | Observational | 2014-03-31 | Recruiting | |||
| A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epileps[NCT00438451] | Phase 4 | 361 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Efficacy, Tolerability and Adherence of the Modified Atkins Diet on Drug-resistant Epilepsy in Adults Patients[NCT03183076] | 14 participants (Actual) | Interventional | 2015-09-01 | Completed | |||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Open Labeled, Non-randomized, Study of Efficacy and Safety of Gralise in Fibromyalgia Patients.[NCT02052414] | 34 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| The Effect of Gabapentin on Prefrontal GABA Concentration and Emotional Processing in Healthy Humans[NCT00094510] | 30 participants (Actual) | Observational | 2004-10-14 | Completed | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| The Efficacy of Gabapentine and Splint Therapy in Bruxers: a Randomized Clinical Trial[NCT01255878] | 20 participants (Actual) | Interventional | 2010-03-31 | Completed | |||
| An Open Prospective Randomised Long-Term Effectiveness Study, Comparing Best Medical Practice With or Without Adjunctive VNS Therapy in Patients 16 Years and Older With Pharmaco-resistant Partial Epilepsy[NCT00522418] | Phase 4 | 122 participants (Actual) | Interventional | 2006-02-28 | Terminated (stopped due to Insufficient enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00438451)
Timeframe: 58 weeks
| Intervention | proportion of participants (Mean) |
|---|---|
| Levetiracetam | 0.61 |
| Carbamazepine | 0.46 |
| Lamotrigine | 0.56 |
Percentage of patients experiencing no seizures until week 58 (Visit 6) and did not discontinue the study until week 58. (NCT00438451)
Timeframe: week 58
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 43 |
| Carbamazepine | 33 |
| Lamotrigine | 38 |
Percentage of patients experiencing no seizures until week 30 (Visit 4) and did not discontinue the study until week 30. (NCT00438451)
Timeframe: Week 30
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 48 |
| Carbamazepine | 39 |
| Lamotrigine | 49 |
(NCT00438451)
Timeframe: 52 weeks
| Intervention | proportion of seizure-free days (Number) |
|---|---|
| Levetiracetam | 0.99 |
| Carbamazepine | 0.99 |
| Lamotrigine | 0.99 |
EPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. The results of EPITrack Score ranges between 7 and 45. (NCT00438451)
Timeframe: week 58
| Intervention | units on a scale (Mean) |
|---|---|
| Levetiracetam | 26.0 |
| Carbamazepine | 26.0 |
| Lamotrigine | 25.4 |
"Seizure frequency was assessed by investigators in the CRF at the Visits V3, V4, V5 and V6.~The absolute seizure frequency during the maintenance phase was defined as the sum of those entries." (NCT00438451)
Timeframe: over 52 weeks
| Intervention | number of seizures (Number) |
|---|---|
| Levetiracetam | 168 |
| Carbamazepine | 131 |
| Lamotrigine | 130 |
(NCT00438451)
Timeframe: over the whole duration of 58 weeks
| Intervention | days (Median) |
|---|---|
| Levetiracetam | NA |
| Carbamazepine | NA |
| Lamotrigine | NA |
number of days between randomization and premature discontinuation of the study (NCT00438451)
Timeframe: 58 weeks
| Intervention | days (Median) |
|---|---|
| Levetiracetam | NA |
| Carbamazepine | 265 |
| Lamotrigine | NA |
"The PNS is a 15-item scale. Each item can be scored from 1 to 9. There are a total score (includes all items, range:15 to 135) and two subscores: The cognitive toxicity subscore (10 items: Energy Level, Memory, Interest, Concentration, Forgetfulness, Sleepliness, Moodiness, Alertness, Attention Span, Motivation, range:10 to 90) and the somatomoto subscore (5 items: Vision, Walking, Coordination, Tremor, Speech, range:5-45). The score is calculated by taking the mean of all non-missing values times the number of items.~Lower values indicate better quality of life." (NCT00438451)
Timeframe: at week 58
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Cognitive toxicity subscore | Somatomotor subscore | Total Score | |
| Carbamazepine | 27.3 | 11.4 | 38.7 |
| Lamotrigine | 23.7 | 10.8 | 34.5 |
| Levetiracetam | 22.2 | 10.5 | 32.7 |
The QOLIE-31 is a 31 item score that measures the quality of life in epilepsy (each item with a range of 0 to 100). There are 7 sub-scores seizure worry (items 11,21,22,23,25), overall quality of life (items 1,14), emotional well-being (items 3,4,5,7,9), energy/fatigue (items 2,6,8,10), cognitive functioning (items 12,15,16,17,18,26), medication effects (items 24,29,30) and social functioning (13,19,20,27,28). These scores were combined to a total score by Total score = seizure worry*0.08 + overall quality of life*0.14 + emotional well-being*0.15 + energy/fatigue*0.12 + cognitive functioning*0.27 + medication effects*0.03 + social functioning*0.21 For all scores, higher values indicate better quality of life. Each score has a possible range from 0 to 100. (NCT00438451)
Timeframe: 58 weeks, final visit
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Seizure worry | Overall quality of life | Emotional well-being | Energy/fatigue | Cognitive functioning | Medication effects | Social functioning | Total Score | Health Scale | |
| Carbamazepine | 75.4 | 65.0 | 69.8 | 54.5 | 68.9 | 70.6 | 76.3 | 68.9 | 65.7 |
| Lamotrigine | 75.0 | 67.1 | 67.4 | 59.8 | 68.0 | 72.6 | 76.7 | 69.1 | 67.5 |
| Levetiracetam | 85.1 | 67.2 | 72.0 | 60.8 | 75.1 | 77.6 | 81.1 | 73.9 | 69.5 |
"Evaluation of current testing at V6:~≥29 score points: Inconspicuous; 26 to 28 score points: Borderline;~≤25 score points: Impaired" (NCT00438451)
Timeframe: 58 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Without pathological findings | Borderline | Impaired | |
| Carbamazepine | 34 | 17 | 33 |
| Lamotrigine | 31 | 15 | 39 |
| Levetiracetam | 38 | 10 | 36 |
"Evaluation of Changes~Changes in the EpiTrack® Score were categorized as follows:~≥5 score points: Improved;~-3 to 4 score points: Unchanged;~≤-4 score points: Worsened" (NCT00438451)
Timeframe: week 58
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Unchanged | Worsened | |
| Carbamazepine | 16 | 56 | 8 |
| Lamotrigine | 15 | 53 | 13 |
| Levetiracetam | 15 | 61 | 6 |
The Fibromyalgia Impact Questionnaire (FIQ) is an instrument designed to quantitate the overall impact of fibromyalgia over many dimensions (e.g. function, pain level, fatigue, sleep disturbance, psychological distress etc.). It is scored from 0 to 100 with the latter number being the worst case. The average score for patients seen in tertiary care settings is about 50. The FIQ is widely used to assess change in fibromyalgia status. (NCT02052414)
Timeframe: 15 weeks.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| FIQ Baseline | FIQ Week 4 | FIQ Week 8 | FIQ Week 12 | FIQ Week 15 | |
| Gralise (Gabapentin ER) | 71.04 | 41.82 | 40.79 | 39.27 | 61.86 |
"Medical Outcomes Study (MOS) sleep questionnaires to assess how Fibromyalgia impacts patients' sleep in various areas.~Specifically, Data reported below measured number of hours subjects spent per night sleeping. MOS sleep questionnaires were assessed at each follow up visits. (visits 1, 2, 3, 4, and 5)." (NCT02052414)
Timeframe: 15 weeks
| Intervention | Hours (Mean) | ||||
|---|---|---|---|---|---|
| Sleep Quantity Baseline | Sleep Quantity week 4 | Sleep quantity week 8 | Sleep quantity week 12 | Sleep quantity week 15 | |
| Gralise (Gabapentin ER) | 5.86 | 7.17 | 6.81 | 7.04 | 6.23 |
Fibromyalgia pain experienced by study subjects will be captured using NPRS at baseline visit, at each follow visits that are scheduled to occur every 4 weeks over 12 weeks of treatment period, and at the end of treatment visit that will occur 3 weeks after treatment period (12 weeks treatment period + 3 weeks = 15 weeks). Any difference in NPRS scores between baseline and any subsequent visits will indicate the magnitude of pain relief as reflected in digital scale of 0-10 (0=no pain, 10=worst pain imaginable). (NCT02052414)
Timeframe: 15 weeks
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| NPRS Baseline (Visit 1) | NPRS on Week 4 (Visit 2) | NPRS on week 8 (Visit 3) | NPRS on Week 12 (Visit 4) | NPRS on week 15 (Visit 5) | |
| Gralise (Gabapentin ER) | 7.29 | 4.72 | 3.95 | 3.83 | 6.94 |
Patient Global impression of Change (PGIC) is an outcome commonly used measure of the efficacy of treatments. PGIC is a 7 point scale that requires the subjects to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT02052414)
Timeframe: 15 Weeks.
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| PGIC After 4 weeks | PGIC After 8 weeks | PGIC After 12 weeks | PGIC After 15 weeks | |
| Gralise (Gabapentin ER) | 4.96 | 5.40 | 5.37 | 4.44 |
Side / adverse effects were assessed at each follow up visits and resulted are as follows. (NCT02052414)
Timeframe: 15 Weeks
| Intervention | participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Extremity Swelling | Weight Gain | Drowsy | Dizzy | Irritability | Dry Eyes | Pain | Mood Changes | Difficulty Concentrating | Dry Mouth | Suspected Drug interaction | Acute Delerium | Adhesion | None | |
| Gralise (Gabapentin ER) | 2 | 2 | 8 | 3 | 3 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 12 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Mean change from baseline AEP Score at 12 months
| Intervention | Units on a scale (Mean) |
|---|---|
| VNS Therapy | -6.0 |
| Best Medical Practice | -3.2 |
The Center for Epidemiologic Studies Depression Scale (CES-D) includes 20 items comprising six scales reflecting major dimensions of depression: depressed mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, psychomotor retardation, loss of appetite, and sleep disturbance. Possible range of scores is 0 to 60, higher scores indicate more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline CES-D Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -2.2 |
| Best Medical Practice | 0.5 |
The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) is a 6-item questionnaire validated to screen for depression in people with epilepsy. Scores range from 6 to 24, with higher scores indicating more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline NDDI-E Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -1.0 |
| Best Medical Practice | -0.2 |
Change from baseline in number of AED medications by visit (NCT00522418)
Timeframe: Change from baseline in number of AEDs at 12 months
| Intervention | Number of AEDs Taken (Median) |
|---|---|
| VNS Therapy | 0 |
| Best Medical Practice | 0 |
The Clinical Global Impression scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention Scores range from 1-7: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT00522418)
Timeframe: Mean change from baseline CGI-I Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -0.8 |
| Best Medical Practice | -0.3 |
Percent change in total seizuires per week from baseline at 12 months (NCT00522418)
Timeframe: Mean percent change from baseline in seizure frequency at 12 months
| Intervention | Percent Change (Mean) |
|---|---|
| VNS Therapy | -19.1 |
| Best Medical Practice | -1.0 |
QOLIE-89 contains 17 multi-item measures of overall quality of life, emotional well-being, role limitations due to emotional problems, social support, social isolation, energy/fatigue, worry about seizure, medication effects, health discouragement, work/driving/social function, attention/concentration, language, memory, physical function, pain, role limitations due to physical problems, and health perceptions. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. (NCT00522418)
Timeframe: Mean change from baseline QOLIE-89 Overall Score at 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| VNS Therapy | 5.5 |
| Best Medical Practice | 1.2 |
Response Rate is defined as the percent of participants who are responders. A Responder is defined as participants with a reduction of at least 50% or 75% in seizure frequency from baseline to the seizure count evaluation period. (NCT00522418)
Timeframe: Number of Responders at 12 Months
| Intervention | participants (Number) |
|---|---|
| VNS Therapy | 10 |
| Best Medical Practice | 7 |
QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| VNS Therapy | Best Medical Practice | |
| Baseline Adverse Event Profile Score < 40 | 3.3 | 0.5 |
QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months
| Intervention | Units on a Scale (Least Squares Mean) | |
|---|---|---|
| VNS Therapy | Best Medical Practice | |
| Baseline Adverse Event Profile Score >= 40 | 3.3 | 0.7 |
113 reviews available for gabapentin and Aura
| Article | Year |
|---|---|
The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches.
Topics: Anticonvulsants; Carbamazepine; Dementia; Epilepsy; Felbamate; Gabapentin; Humans; Inflammasomes; La | 2022 |
Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force
Topics: Breast Feeding; Cannabidiol; Carbamazepine; Child; Clobazam; Clonazepam; Epilepsy; Ethosuximide; Eve | 2022 |
Second Generation of Antiepileptic Drugs and Oxidative Stress.
Topics: Anticonvulsants; Carbamazepine; Diazepam; Epilepsy; Epilepsy, Generalized; Fructose; Gabapentin; Hum | 2023 |
Gabapentin monotherapy for epilepsy: A review.
Topics: Anticonvulsants; Carbamazepine; Drug Resistant Epilepsy; Epilepsies, Partial; Epilepsy; Gabapentin; | 2023 |
Antiepileptic drug monotherapy for epilepsy in the elderly: A systematic review and network meta-analysis.
Topics: Aged; Anticonvulsants; Carbamazepine; Epilepsy; Female; Gabapentin; Humans; Levetiracetam; Male; Net | 2019 |
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Topics: Acetylcysteine; Animals; Anticonvulsants; Antioxidants; Atorvastatin; Brain Injuries, Traumatic; Cef | 2020 |
[Transfer Mechanisms of Compounds between Mother and Fetus/Infant Aimed for Optimized Medication during Pregnancy and Breastfeeding].
Topics: Anticonvulsants; Benzodiazepines; Biological Transport; Breast Feeding; Cell Line; Epilepsy; Female; | 2020 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
Extended-release drug formulations for the treatment of epilepsy.
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Delayed-Action Preparations; Dr | 2018 |
Choice of therapeutic anti-seizure medication in patients with brain tumour.
Topics: Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Epilepsy; Gabapentin; Glioma; Humans; L | 2019 |
[Treatment of pediatric epilepsy].
Topics: Adolescent; Amines; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cyclohexanecarboxylic A | 2014 |
[New antiepileptic drugs: characteristics and clinical applications].
Topics: Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dioxolanes; Drug App | 2014 |
[Preconceptional and perinatal challenges of pregnancy in women with epilepsy].
Topics: Adult; Amines; Anticonvulsants; Benzodiazepines; Carbamazepine; Cyclohexanecarboxylic Acids; Epileps | 2016 |
Reporting and analysis of open-label extension studies of anti-epileptic drugs.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Databases, Factual; Drug Resistance; Epilepsy; | 2008 |
Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy.
Topics: Amines; Animals; Anticonvulsants; Calcium Channels, L-Type; Clinical Trials as Topic; Cognition; Cyc | 2008 |
New pharmacotherapies for pediatric seizures.
Topics: Adolescent; Amines; Animals; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cyclohexanecar | 2004 |
Behavioral and cognitive effects of anti-epileptic drugs.
Topics: Amines; Anticonvulsants; Antidepressive Agents; Behavior; Cognition; Cognition Disorders; Cyclohexan | 2010 |
Psychiatric concerns in pediatric epilepsy.
Topics: Adolescent; Amines; Anxiety Disorders; Bipolar Disorder; Child; Child, Preschool; Cyclohexanecarboxy | 2010 |
[Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications].
Topics: Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Antineoplastic Agents; Carbamazepine; Cohor | 2011 |
Ca2+ channels and epilepsy.
Topics: Acetates; Amines; Calcium Channels; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; gamma-Aminobu | 2002 |
[Characteristics and indications of gabapentin].
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Child; Child, Prescho | 2002 |
Antiepileptic drug therapy for adults: when to initiate and how to choose.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Felb | 2002 |
New antiepileptic drug therapies.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Ep | 2002 |
Gabapentin dosing in the treatment of epilepsy.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Child, Preschool; Clinical Trials as Topic; Cyclohe | 2003 |
Gabapentin and lamotrigine: novel antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Epilepsy; | 1995 |
The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
Topics: Acetates; Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interac | 2003 |
Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epileps
Topics: Acetates; Acute Disease; Adolescent; Adult; Amines; Anticonvulsants; Carbamazepine; Child; Controlle | 2004 |
New antiepileptic drugs that are second generation to existing antiepileptic drugs.
Topics: Amines; Animals; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Drug | 2006 |
Novel anticonvulsant drugs.
Topics: Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Fructose; Ga | 2007 |
Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interactions; Drug Monitor | 2006 |
[Newer antiepileptic drugs].
Topics: Amines; Animals; Anti-Anxiety Agents; Anticonvulsants; Calcium Channel Blockers; Carbamazepine; Cycl | 2007 |
Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia.
Topics: Aged; Aged, 80 and over; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2007 |
Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms.
Topics: Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Fructose; Gabapentin; gamma | 2007 |
[Epilepsy in the elderly].
Topics: Aged; Aged, 80 and over; Aging; Amines; Anticonvulsants; Cerebrovascular Disorders; Comorbidity; Cyc | 2007 |
Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels.
Topics: Amines; Animals; Calcium Channel Blockers; Calcium Channels; Cell Membrane; Cerebellar Ataxia; Cyclo | 2007 |
The new antiepileptic drugs.
Topics: Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Epilepsies, | 2007 |
[Current viewpoints in the treatment of epilepsies: role of new antiepileptics?].
Topics: 4-Aminobutyrate Transaminase; Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxyli | 1995 |
Mechanisms of action of currently prescribed and newly developed antiepileptic drugs.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Drugs, Investigational; Epi | 1994 |
Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy.
Topics: Acetates; Amines; Animals; Anticonvulsants; Biological Availability; Clinical Trials as Topic; Cyclo | 1993 |
[New antiepileptic medications].
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; | 1995 |
Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options.
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam | 1995 |
New antiepileptic drugs--an explosion of activity.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Approval; Drug Interactions; Dr | 1995 |
New antiepileptic drugs for children: felbamate, gabapentin, lamotrigine, and vigabatrin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Approval; Epileps | 1994 |
Gabapentin: a new agent for the management of epilepsy.
Topics: Acetates; Adult; Age Factors; Amines; Anticonvulsants; Controlled Clinical Trials as Topic; Cyclohex | 1994 |
Gabapentin.
Topics: Acetates; Adult; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Interactions; E | 1994 |
Newer antiepileptic drugs. Towards an improved risk-benefit ratio.
Topics: Acetamides; Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dioxolane | 1994 |
New anti-epileptic drugs in the 1990s.
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam | 1994 |
Guidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin.
Topics: Acetates; Adult; Amines; Animals; Anticonvulsants; Child; Clinical Protocols; Controlled Clinical Tr | 1994 |
Phenobarbitone to gabapentin: a guide to 82 years of anti-epileptic drug pharmacokinetic interactions.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Interactions; Epilepsy; Gabapen | 1994 |
Clinical pharmacokinetics of gabapentin.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Interactions; Epilepsy; Gabapen | 1994 |
Clinical efficacy and safety of gabapentin.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Ep | 1994 |
Drug therapy for epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Decision Trees; Epilepsy; Felbamate; | 1994 |
Antiepileptic drugs in development: prospects for the near future.
Topics: Acetates; Adult; Amines; Aminocaproates; Animals; Anticonvulsants; Clinical Trials as Topic; Cyclohe | 1994 |
Advances in pharmacotherapy: recent developments in the treatment of epilepsy.
Topics: Acetates; Amines; Aminocaproates; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Aci | 1993 |
Antiepileptic drugs in clinical development.
Topics: Acetates; Amines; Aminocaproates; Anticonvulsants; Brain; Clinical Trials as Topic; Cyclohexanecarbo | 1993 |
[Diagnosis and therapy of epilepsy and myoclonus].
Topics: Acetates; Amines; Cerebral Cortex; Cyclohexanecarboxylic Acids; Electrophysiology; Epilepsy; Gabapen | 1993 |
Advances in the pharmacotherapy of epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Gabapentin; gam | 1993 |
[Refractory epilepsy in adults and the new antiepileptic drugs: the role of gabapentin].
Topics: Acetates; Amines; Anticonvulsants; Chile; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dru | 1995 |
Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Carbamazepine; Clinical Trials as Topic; | 1996 |
Utilization of new antiepileptic drugs in children.
Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Anticonvulsants; Carbamazepine; Child; Child, Pres | 1996 |
[Advances in the diagnostic and treatment of infantile epilepsy].
Topics: Acetates; Amines; Anticonvulsants; Brain; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Elec | 1996 |
[Current anti-epilepsy drugs].
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Therapy, Combina | 1995 |
Mechanisms of action of antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; GABA Antagonists; Gabapent | 1995 |
Antiepileptic drug mechanisms of action.
Topics: Acetates; Action Potentials; Amines; Animals; Anticonvulsants; Barbiturates; Benzodiazepines; Calciu | 1995 |
Gabapentin.
Topics: Acetates; Adult; Amines; Animals; Anticonvulsants; Child; Clinical Trials as Topic; Cyclohexanecarbo | 1995 |
Important pharmacokinetic properties of antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Biopharmaceutics; Carbamazepine; Cyclohe | 1995 |
Diagnosis and treatment of epilepsy in children and adolescents.
Topics: Acetates; Adolescent; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids; | 1996 |
New antiepileptic drugs: a systematic review of their efficacy and tolerability.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Child; Cross-Over Studies; Cyclohexaneca | 1996 |
Pharmacokinetics of new antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Carbamazepine; Cyclohexanecarboxylic Aci | 1996 |
Update on the mechanism of action of antiepileptic drugs.
Topics: 4-Aminobutyrate Transaminase; Acetamides; Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecar | 1996 |
The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps.
Topics: Acetates; Amines; Anticonvulsants; Cerebral Palsy; Cyclohexanecarboxylic Acids; Disabled Persons; Dr | 1996 |
Clinical administration of new antiepileptic drugs: an overview of safety and efficacy.
Topics: Acetates; Amines; Anticonvulsants; Confidence Intervals; Cyclohexanecarboxylic Acids; Drug Interacti | 1996 |
[Advantages and disadvantages of new antiepileptic drugs].
Topics: Acetates; Adrenocorticotropic Hormone; Amines; Anticonvulsants; Brain; Cyclohexanecarboxylic Acids; | 1996 |
[Treatment of the epilepsy: new drugs].
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamaz | 1996 |
The new antiepileptic drugs.
Topics: Abnormalities, Drug-Induced; Acetates; Adolescent; Adult; Amines; Anticonvulsants; Child; Child, Pre | 1996 |
New antiepileptic drugs.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; F | 1996 |
New antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; | 1996 |
Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Interactions; Drug Monitoring; | 1997 |
Overview of the safety of newer antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drug Inter | 1997 |
[New antiepileptic drugs].
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Gabapentin; gam | 1997 |
Pharmacologic and dietary therapies in epilepsy: conventional treatments and recent advances.
Topics: Acetates; Amines; Anticonvulsants; Benzodiazepines; Carbamazepine; Cyclohexanecarboxylic Acids; Epil | 1997 |
Recent advancements in epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose; Gabap | 1997 |
A review of the newer antiepileptic drugs and the ketogenic diet.
Topics: Acetates; Age Factors; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids | 1997 |
Gabapentin for treatment of epilepsy in children.
Topics: Acetates; Adolescent; Adult; Amines; Animals; Anticonvulsants; Child; Clinical Trials as Topic; Cycl | 1997 |
Overview of lamotrigine and the new antiepileptic drugs: the challenge.
Topics: Acetates; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Interactions; Epilepsy; | 1997 |
Advances in the medical treatment of epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Diazepam; Drug Approv | 1998 |
Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Acetates; Amines; Anticonvulsants; Brain; Brain Chemistry; Cyclohexane | 1998 |
Monotherapy clinical trials of new antiepileptic drugs: design, indications, and controversies.
Topics: Acetates; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Double-Bli | 1997 |
The new antiepileptic drugs: a systematic review of their efficacy and tolerability.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug | 1997 |
New antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Approval; Epilep | 1998 |
Antiepileptic drug therapy.
Topics: Acetates; Amines; Animals; Anticonvulsants; Bromides; Cat Diseases; Cats; Cyclohexanecarboxylic Acid | 1998 |
Gabapentin. Antiepileptic mechanism of action.
Topics: Acetates; Action Potentials; Amines; Animals; Anticonvulsants; Calcium Channels; Cyclohexanecarboxyl | 1998 |
Lamotrigine and gabapentin. Alternative in the treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Clinic | 1998 |
Fortnightly review: drug treatment of epilepsy.
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Barbiturates; Benzodiazepines; Clobazam; Clo | 1999 |
New medication options for patients with epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose; Gabap | 1998 |
New antiepileptic drugs: comparison of key clinical trials.
Topics: Acetates; Amines; Anticonvulsants; Controlled Clinical Trials as Topic; Cyclohexanecarboxylic Acids; | 1999 |
Options after the first antiepileptic drug has failed.
Topics: Acetates; Amines; Anticonvulsants; Attitude to Health; Carbamazepine; Clinical Trials as Topic; Cycl | 1999 |
Monostars: an aid to choosing an antiepileptic drug as monotherapy.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Administration S | 1999 |
Use of new antiepileptic drugs in the treatment of childhood epilepsy.
Topics: Acetates; Adult; Age Factors; Amines; Anticonvulsants; Child; Clinical Trials as Topic; Cyclohexanec | 1999 |
Gabapentin in the management of convulsive disorders.
Topics: Acetates; Action Potentials; Amines; Animals; Anticonvulsants; Clinical Trials as Topic; Cyclohexane | 1999 |
Gabapentin.
Topics: Acetates; Amines; Anticonvulsants; Controlled Clinical Trials as Topic; Cyclohexanecarboxylic Acids; | 1999 |
Managing pediatric epilepsy syndromes with new antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose | 1999 |
The clinical pharmacokinetics of the new antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Cyclohexanecarboxylic Acids; Dose-Respon | 1999 |
[GABA-ergic system and antiepileptic drugs].
Topics: Acetates; Amines; Anticonvulsants; Binding, Competitive; Calcium Channels; Chloride Channels; Cycloh | 2000 |
New antiepileptic drugs.
Topics: Acetates; Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interac | 2000 |
[Current data on gabapentin].
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Drug | 2000 |
Therapeutic safety monitoring: what to look for and when to look for it.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Monitoring; Epil | 2000 |
New antiepileptic drugs and preparations.
Topics: Acetates; Administration, Rectal; Age Factors; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; | 2000 |
Cognitive side effects of anticonvulsants.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cognition Disorders; Cyclohexane | 2001 |
Lamotrigine update and its use in mood disorders.
Topics: Acetates; Aggression; Amines; Antidepressive Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; | 2002 |
Background and rationale for use of anticonvulsants in psychiatry.
Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cycloh | 1998 |
Gabapentin.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Drugs, Investigational; Ele | 1991 |
23 trials available for gabapentin and Aura
| Article | Year |
|---|---|
Analysis of exposure-response of CI-945 in patients with epilepsy: application of novel mixed hidden Markov modeling methodology.
Topics: Adolescent; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Dose-Response Relati | 2012 |
Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Asthenia; Clinical Protocols; Cyclohexan | 2002 |
The absorption of gabapentin following high dose escalation.
Topics: Absorption; Acetates; Amines; Anticonvulsants; Biological Availability; Cyclohexanecarboxylic Acids; | 2003 |
New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine.
Topics: Aged; Aging; Amines; Anticonvulsants; Carbamazepine; Cerebral Infarction; Cyclohexanecarboxylic Acid | 2005 |
[Efficacy, safety and effect on the quality of life of gabapentin in adult epilepsy--results of a prospective open-label quasi naturalistic Hungarian multicenter study (phase human-IV)].
Topics: Adult; Aged; Ambulatory Care Facilities; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epile | 2006 |
A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Female; Fructo | 2007 |
Long-term study with gabapentin in patients with drug-resistant epileptic seizures.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Double-Blind Method; Epilepsy | 1994 |
Effect of gabapentin (Neurontin) [corrected] on mood and well-being in patients with epilepsy.
Topics: Acetates; Adult; Affect; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Gab | 1996 |
Oral gabapentin disposition in patients with epilepsy after a high-protein meal.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dietary Proteins; Epilepsy; F | 1997 |
Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy.
Topics: Acetates; Adult; Amines; Anticonvulsants; Biological Availability; Cyclohexanecarboxylic Acids; Epil | 1998 |
Effects of gabapentin on cognition and quality of life in patients with epilepsy.
Topics: Acetates; Adult; Affect; Aged; Amines; Anticonvulsants; Cognition; Cyclohexanecarboxylic Acids; Epil | 1998 |
Adjunctive therapy in epilepsy with new antiepileptic drugs: is it of any value?
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clobazam; Cyclohexanecarbox | 1998 |
Gabapentin add-on treatment: how many patients become seizure-free? An open-label multicenter study.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; F | 1999 |
An audit of the perceived efficacy and tolerability of gabapentin therapy in an out-patient cohort with chronic epilepsy.
Topics: Acetates; Adult; Ambulatory Care; Amines; Anticonvulsants; Chronic Disease; Cohort Studies; Cyclohex | 1999 |
Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study.
Topics: Acetates; Adolescent; Adult; Ambulatory Care; Amines; Anticonvulsants; Asthenia; Carbamazepine; Cycl | 1999 |
[Visual field defects due to antiepileptic drugs].
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dr | 1999 |
Gabapentin in childhood epilepsy: a prospective evaluation of efficacy and safety.
Topics: Acetates; Adolescent; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids; | 2000 |
Effect of anticonvulsants on nocturnal sleep in epilepsy.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Circadian Rhythm; Cyclohexanecarboxylic Aci | 2000 |
Gabapentin as add-on therapy in children with refractory partial seizures: a 24-week, multicentre, open-label study.
Topics: Acetates; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Double-Blin | 2001 |
A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Administrati | 2001 |
Population pharmacokinetics of gabapentin in infants and children.
Topics: Acetates; Adolescent; Amines; Anticonvulsants; Body Weight; Child; Child, Preschool; Creatinine; Cyc | 2001 |
Effects of gabapentin and carbamazepine on the EEG and cognition in healthy volunteers.
Topics: Acetates; Adolescent; Adult; Alpha Rhythm; Amines; Anticonvulsants; Brain; Carbamazepine; Cognition; | 2002 |
Gabapentin as an antiepileptic drug in man.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxyli | 1987 |
125 other studies available for gabapentin and Aura
| Article | Year |
|---|---|
Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.
Topics: Adamantane; Animals; Azides; Epilepsy; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Mice; Neura | 2010 |
Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112).
Topics: Absorption; Amides; Animals; Anticonvulsants; Dioxanes; Dogs; Drug Evaluation, Preclinical; Drug Res | 2013 |
Antiseizure medication treatment pathways for US Medicare beneficiaries with newly treated epilepsy.
Topics: Aged; Anticonvulsants; Epilepsy; Gabapentin; Humans; Lacosamide; Lamotrigine; Levetiracetam; Medicar | 2022 |
Association between anti-seizure medication and the risk of lower urinary tract infection in patients with epilepsy.
Topics: Adult; Anti-Bacterial Agents; Anticonvulsants; Carbamazepine; Epilepsy; Female; Gabapentin; Humans; | 2022 |
Pathophysiological Roles of Auxiliary Calcium Channel α
Topics: Calcium; Calcium Channels; Epilepsy; Gabapentin; Humans; Neurons; Protein Subunits; Synapses | 2023 |
Channeling of New Neuropsychiatric Drugs-Impact on Safety and Effectiveness Studies.
Topics: Adult; Cross-Sectional Studies; Diabetic Neuropathies; Epilepsy; Gabapentin; Humans; Levetiracetam; | 2023 |
Association of first anti-seizure medication choice with injuries in older adults with newly diagnosed epilepsy.
Topics: Aged; Anticonvulsants; Brain Injuries, Traumatic; Epilepsy; Gabapentin; Humans; Reinjuries; Retrospe | 2023 |
Insight on the hub gene associated signatures and potential therapeutic agents in epilepsy and glioma.
Topics: Area Under Curve; Cell Communication; Epilepsy; Gabapentin; Glioma; Humans | 2023 |
Prescribing Trends of Antiseizure Drugs in Women Veterans With Epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Gabapentin; Humans; Lamotrigine; Levetiracetam | 2023 |
Utilization of Antiseizure Medications in Women of Childbearing Age With Epilepsy and Nonepilepsy Indications: A Retrospective Cohort Study.
Topics: Anticonvulsants; Clonazepam; Diazepam; Epilepsy; Female; Gabapentin; Humans; Lamotrigine; Lorazepam; | 2023 |
Antiepileptic combination therapy with Stevens-Johnson syndrome and toxic epidermal necrolysis: Analysis of a Japanese pharmacovigilance database.
Topics: Anticonvulsants; Carbamazepine; Clobazam; Clonazepam; Databases, Factual; Drug Therapy, Combination; | 2020 |
Gabapentin treatment in a patient with KCNQ2 developmental epileptic encephalopathy.
Topics: Age of Onset; Animals; Anticonvulsants; Carbamates; Cells, Cultured; Child; CHO Cells; Cricetinae; C | 2020 |
Persistence with antiepileptic drugs in epilepsy patients treated in neurological practices in Germany.
Topics: Adult; Age Factors; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Ga | 2017 |
Factors in Variability of Serial Gabapentin Concentrations in Elderly Patients with Epilepsy.
Topics: Aged; Amines; Anticonvulsants; Biological Availability; Biological Variation, Individual; Cyclohexan | 2017 |
Effects of the Antiepileptic Drugs Phenytoin, Gabapentin, and Levetiracetam on Bone Strength, Bone Mass, and Bone Turnover in Rats.
Topics: Administration, Oral; Amines; Animals; Anticonvulsants; Bone Density; Bone Remodeling; Bone Resorpti | 2017 |
Nonlesional late-onset epilepsy: Semiology, EEG, cerebrospinal fluid, and seizure outcome characteristics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Electroencephalography; Epilepsy; Femal | 2019 |
Effects of androsterone on the protective action of various antiepileptic drugs against maximal electroshock-induced seizures in mice.
Topics: Androgens; Androsterone; Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Disease | 2019 |
Hypothyroidism induced by phenytoin and gabapentin: A Case Report.
Topics: Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; gamma-Aminobutyric | 2018 |
Therapeutic drug monitoring of gabapentin in various indications.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Child; Child, Preschool; Drug Monitorin | 2019 |
Effect of gabapentin on sleep patterns disturbed by epilepsy.
Topics: Animals; Anticonvulsants; Dose-Response Relationship, Drug; Electrooculography; Epilepsy; Gabapentin | 2019 |
A Call for Caution in Prescribing Gabapentin to Individuals With Concurrent Polysubstance Abuse: A Case Report.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Gabapentin; Humans; Substance-Related Disorders | 2019 |
Use of antiepileptic drugs in women of fertile age.
Topics: Adolescent; Adult; Anticonvulsants; Denmark; Epilepsy; Female; Gabapentin; Humans; Lamotrigine; Leve | 2019 |
Delirium after gabapentin withdrawal. Case report.
Topics: Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Delirium; Electroencephalography; Epilep | 2013 |
Epilepsy and brain injury: a case report of a dramatic neuropsychiatric vicious circle.
Topics: Accidents, Traffic; Aggression; Amines; Anterior Temporal Lobectomy; Anticonvulsants; Brain Injuries | 2013 |
Glia and epilepsy: experimental investigation of antiepileptic drugs in an astroglia/microglia co-culture model of inflammation.
Topics: Amines; Animals; Anticonvulsants; Astrocytes; Blotting, Western; Carbamazepine; Cells, Cultured; Coc | 2014 |
Gabapentin attenuates hyperexcitability in the freeze-lesion model of developmental cortical malformation.
Topics: Age Factors; Amines; Animals; Animals, Newborn; Anticonvulsants; Calcium Channels; Cyclohexanecarbox | 2014 |
Effects of intravenous human umbilical cord blood mesenchymal stem cell therapy versus gabapentin in pentylenetetrazole-induced chronic epilepsy in rats.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Epilepsy; Female; Gabapentin; | 2014 |
Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice.
Topics: Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; | 2015 |
Comparative persistence of antiepileptic drugs in patients with epilepsy: A STROBE-compliant retrospective cohort study.
Topics: Adolescent; Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilep | 2016 |
Retention rates of new antiepileptic drugs in localization-related epilepsy: a single-center study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Ac | 2009 |
Retention of new AEDs in institutionalized intellectually disabled patients with epilepsy.
Topics: Adolescent; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Utilization Rev | 2009 |
Probability of rash related to gabapentin therapy in a child.
Topics: Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy; Exanthema; Gabapentin; gamma- | 2009 |
[New antiepileptic drugs].
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsies, Partial; Epilepsy; | 2009 |
Novel long-term anticonvulsant treatment with gabapentin without causing memory impairment in mice.
Topics: Amines; Animals; Anticonvulsants; Cognition Disorders; Cyclohexanecarboxylic Acids; Disease Models, | 2010 |
Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy.
Topics: Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dose-Response Rela | 2010 |
Paroxysmal arousals and myoclonic movements associated with interictal epileptiform discharges in NREM and REM sleep.
Topics: Adolescent; Amines; Antiparkinson Agents; Arousal; Chromosome Disorders; Chromosome Inversion; Chrom | 2011 |
[Clinical characteristics and treatment for new onset epilepsy in the elderly].
Topics: Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Diagnostic Imaging; Elect | 2010 |
Off-label gabapentin masking ictal triphasic waves: case analysis of neuropsychiatric and electrographic correlates.
Topics: Administration, Oral; Aged; Amines; Anticonvulsants; Brain Waves; Cyclohexanecarboxylic Acids; Elect | 2011 |
Retention rate of Gabapentin in children with intractable epilepsies at 1 year.
Topics: Adolescent; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Epilepsy; | 2012 |
The amygdala to periaqueductal gray pathway: plastic changes induced by audiogenic kindling and reversal by gabapentin.
Topics: Acoustic Stimulation; Action Potentials; Amines; Amygdala; Animals; Cyclohexanecarboxylic Acids; Ele | 2012 |
[Clinical application of newer anti-epileptic drugs].
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Fructose; Gabapentin; gamma- | 2012 |
[Psychomotor slowness of a mentally retarded woman].
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clobazam; Cyclohexan | 2001 |
Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis.
Topics: Acetates; Amines; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarboxylic Acids; Disease M | 2002 |
A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England.
Topics: Acetates; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 an | 2002 |
Down-regulation of N-type voltage-activated Ca2+ channels by gabapentin.
Topics: Acetates; Action Potentials; Amines; Amino Acid Transport System L; Animals; Anticonvulsants; Brain; | 2002 |
[Edematous syndrome and alithiasic cholecystitis induced by gabapentin].
Topics: Acetates; Adult; Amines; Anticonvulsants; Cholecystitis; Cyclohexanecarboxylic Acids; Edema; Epileps | 2002 |
Gabapentin-induced bullous pemphigoid.
Topics: Acetates; Amines; Anticonvulsants; Azathioprine; Cyclohexanecarboxylic Acids; Drug Therapy, Combinat | 2002 |
Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response.
Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Analysis of Variance; Child; Child, Preschool; Cyc | 2003 |
Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Gabapentin; | 2003 |
Gabapentin actions on Kir3 currents and N-type Ca2+ channels via GABAB receptors in hippocampal pyramidal cells.
Topics: Acetates; Action Potentials; Amines; Animals; Anticonvulsants; Baclofen; Barium; Calcium Channel Blo | 2003 |
Limited efficacy of gabapentin in severe therapy-resistant epilepsies of learning-disabled patients.
Topics: Acetates; Amines; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; gamma-Aminobutyric Acid; Humans | 2003 |
entla, a novel epileptic and ataxic Cacna2d2 mutant of the mouse.
Topics: Acetates; Alleles; Amines; Animals; Ataxia; Base Sequence; Blotting, Southern; Blotting, Western; Ca | 2004 |
Potentially inappropriate antiepileptic drugs for elderly patients with epilepsy.
Topics: Acetates; Aged; Amines; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Epilepsy; Female; Ga | 2004 |
Interaction between anticonvulsants and human placental carnitine transporter.
Topics: Acetates; Amines; Aminoisobutyric Acids; Anticonvulsants; Carnitine; Carrier Proteins; Culture Techn | 2004 |
Determination of gabapentin-lactam in serum of patients under gabapentin therapy.
Topics: Acetates; Adult; Amines; Anticonvulsants; Aza Compounds; Chromatography, Ion Exchange; Cyclohexaneca | 2004 |
Out with the old and in with the new...epilepsy drugs.
Topics: Acetates; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Drug Therapy; Epilepsy; Gab | 2004 |
Effect of L-type calcium channel antagonists on spermine-induced CNS excitation in vivo.
Topics: Amines; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Central Nervous System; Convuls | 2005 |
Antiepileptic drugs for the elderly: using the old to focus on the new.
Topics: Age Factors; Aged; Aged, 80 and over; Amines; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; | 2005 |
Evaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugs.
Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Fructose; Gabapentin; | 2005 |
Effects of anticonvulsants on soman-induced epileptiform activity in the guinea-pig in vitro hippocampus.
Topics: Amines; Animals; Anticonvulsants; Carbamates; Carbamazepine; Chlormethiazole; Clozapine; Cyclohexane | 2005 |
Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy?
Topics: Amines; Anticonvulsants; Breast Feeding; Cyclohexanecarboxylic Acids; Epilepsy; Female; Fetal Blood; | 2005 |
New antiepileptic drugs in practice--how do they perform in the real world?
Topics: Amines; Anticonvulsants; Controlled Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Epilepsy; | 2005 |
Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent.
Topics: Amines; Animals; Anticonvulsants; Bromides; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Dog | 2005 |
K(+)-evoked [(3)H]-norepinephrine release in human brain slices from epileptic and non-epileptic patients is differentially modulated by gabapentin and pinacidil.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Amines; Anticonvulsants; Brimonidine Tartrate; Calcium Chann | 2006 |
Measuring the effects of antiepileptic medications on balance in older people.
Topics: Aged; Amines; Anticonvulsants; Ataxia; Carbamazepine; Cyclohexanecarboxylic Acids; Dizziness; Epilep | 2006 |
Intraventricular administration of gabapentin in the rat increases flurothyl seizure threshold.
Topics: Amines; Animals; Anticonvulsants; Brain; Brain Chemistry; Cerebral Cortex; Convulsants; Cyclohexanec | 2007 |
Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005.
Topics: Adolescent; Adult; Age Distribution; Aged; Amines; Anticonvulsants; Carbamazepine; Catchment Area, H | 2007 |
Cerebellar cognitive affective syndrome associated with topiramate.
Topics: Amines; Anticonvulsants; Carbamazepine; Cerebellar Diseases; Cerebellum; Cognition Disorders; Cycloh | 2008 |
New antiepileptic drugs in pediatric epilepsy.
Topics: Amines; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Epilep | 2008 |
The role of newer anticonvulsants in the management of epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Australia; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; gam | 1995 |
New drugs for the treatment of epilepsy.
Topics: Acetates; Amines; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Gabape | 1995 |
Gabapentin (NEURONTIN)--a novel anticonvulsant.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; gamma-Aminobut | 1994 |
Gabapentin treatment of seizures in acute intermittent porphyria.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; gamma-A | 1995 |
Neurontin--1 year on. London October 1994.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Approval; Epilepsy; Gabapentin; | 1995 |
FDA approved new drug bulletin. Gabapentin (neurontin).
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Interactions; Epilepsy; | 1994 |
Novel antiepileptic drugs: nursing implications.
Topics: Acetates; Amines; Aminocaproates; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Approval; Drug | 1993 |
Science reporters hear wide range of recent data at 12th annual conference.
Topics: Acetates; Aged; AIDS Vaccines; American Medical Association; Amines; Animals; Anticonvulsants; beta- | 1993 |
New antiepileptic medications.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Dr | 1995 |
Costing of antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Argentina; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Costs | 1996 |
[Gabapentin--a new add-on antiepileptic drug].
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; gamma-Aminobut | 1996 |
[Current role of novel antiepileptics in the treatment of epilepsies].
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Resistance; Epil | 1996 |
[Recommendations on clinical epilepsy treatment using gabapentin].
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Child; Contraindications; Cyclohexanecarboxyli | 1996 |
Behavioral side effects of gabapentin in children.
Topics: Acetates; Aggression; Akathisia, Drug-Induced; Amines; Anticonvulsants; Attention Deficit Disorder w | 1996 |
Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin.
Topics: Acetates; Adolescent; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; ga | 1996 |
Epilepsy in porphyria.
Topics: 5-Aminolevulinate Synthetase; Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; | 1996 |
[New medical treatment of epilepsy].
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Costs; Epile | 1996 |
An audit of the new antiepileptic drugs in clinical neurological practice.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Gabapentin; | 1996 |
Movement disorders associated with the use of gabapentin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Benzodiazepines; Cyclohexanecarboxylic Acids; Dyskinesia, | 1996 |
Hypomania induced by gabapentin.
Topics: Acetates; Affect; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Electroenc | 1995 |
Gabapentin interaction with felbamate.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Interactions; Epilepsy; | 1996 |
If comparisons can be odious, so can assumptions.
Topics: Acetates; Amines; Anticonvulsants; Cost-Benefit Analysis; Cyclohexanecarboxylic Acids; Epilepsy; Gab | 1996 |
Gabapentin.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; gamma-Aminobut | 1996 |
The anticonvulsant gabapentin decreases firing rates of substantia nigra pars reticulata neurons.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Gabapenti | 1996 |
New treatment options for epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose; Gabap | 1997 |
New antiepileptic drugs: case studies.
Topics: Acetates; Amines; Anticonvulsants; Child, Preschool; Cyclohexanecarboxylic Acids; Drug Resistance; E | 1997 |
Incontinence during treatment with gabapentin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy; Fecal Incont | 1997 |
A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities.
Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Comorbidity; Cyclohexanecarboxylic Acids; Dose-Respo | 1997 |
[Gabapentine--advances in the management of epilepsy].
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; gamma-Aminobut | 1994 |
[Gabapentin--a new anti-epileptic agent].
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; gamma-Aminobut | 1994 |
Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients.
Topics: Acetates; Adult; Amines; Anticonvulsants; Athetosis; Chorea; Cyclohexanecarboxylic Acids; Epilepsy; | 1997 |
Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dos | 1997 |
[GabapentinE++--improved treatment possibility for epilepsy].
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; gamma-Aminobut | 1994 |
[Gabapentin--a new antiepileptic agent].
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic | 1998 |
Failure of absorption of gabapentin after rectal administration.
Topics: Acetates; Administration, Oral; Administration, Rectal; Adolescent; Amines; Anticonvulsants; Biologi | 1997 |
Identification of novel ligands for the gabapentin binding site on the alpha2delta subunit of a calcium channel and their evaluation as anticonvulsant agents.
Topics: Acetates; Amines; Animals; Anticonvulsants; Binding Sites; Calcium Channels; Cyclohexanecarboxylic A | 1998 |
Gabapentin potentiation of the antiepileptic efficacy of vigabatrin in an in vitro model of epilepsy.
Topics: 4-Aminobutyrate Transaminase; Acetates; Amines; Animals; Anticonvulsants; Bicuculline; Cyclohexaneca | 1998 |
The outcome of prescribing novel anticonvulsants in an outpatient setting: factors affecting response to medication.
Topics: Acetates; Adolescent; Adult; Ambulatory Care; Amines; Anticonvulsants; Chi-Square Distribution; Cycl | 1998 |
Treatment of seizures in acute intermittent porphyria: safety and efficacy of gabapentin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Gabapentin; | 1998 |
The management of epilepsy in a hospital for people with a learning disability.
Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Uti | 1999 |
The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy.
Topics: Acetates; Ambulatory Care; Amines; Anticonvulsants; Chronic Disease; Clinical Trials as Topic; Cyclo | 1999 |
Refractory epilepsy: treatment with new antiepileptic drugs.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Resist | 2000 |
Gabapentin, an antiepileptic drug, improves memory storage in mice.
Topics: Acetates; Amines; Animals; Anticonvulsants; Brain; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin | 2000 |
Gabapentin prophylaxis of clozapine-induced seizures.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Antipsychotic Agents; Clozapine; Cyclohexaneca | 2000 |
Myoclonus associated with the use of gabapentin.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Rel | 2000 |
Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients.
Topics: Acetates; Adult; Amines; Anticonvulsants; Brain Chemistry; Carnosine; Cyclohexanecarboxylic Acids; D | 2000 |
Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients.
Topics: Acetates; Adult; Amines; Anticonvulsants; Brain Chemistry; Carnosine; Cyclohexanecarboxylic Acids; D | 2000 |
Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients.
Topics: Acetates; Adult; Amines; Anticonvulsants; Brain Chemistry; Carnosine; Cyclohexanecarboxylic Acids; D | 2000 |
Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients.
Topics: Acetates; Adult; Amines; Anticonvulsants; Brain Chemistry; Carnosine; Cyclohexanecarboxylic Acids; D | 2000 |
Gabapentin-induced modulation of interictal epileptiform activity related to different vigilance levels.
Topics: Acetates; Adult; Amines; Arousal; Cyclohexanecarboxylic Acids; Electroencephalography; Epilepsy; Fem | 2000 |
[Clinical utilization of new anti-epileptic agents].
Topics: Acetates; Amines; Anemia, Aplastic; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dru | 2000 |
Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy.
Topics: Acetates; Adolescent; Adult; Age of Onset; Aged; Amines; Anticonvulsants; Chronic Disease; Cyclohexa | 2000 |
Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom.
Topics: Acetates; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Amines; Anticonvulsants; | 2001 |
Effects of antiepileptic drugs on cognition.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cognition; Cognition Disorders; Cyclohexanecarboxy | 2001 |
Gabapentin neurotoxicity in a chronic haemodialysis patient.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Epilepsy, Absence; | 2001 |
Pregnancy registries in epilepsy.
Topics: Abnormalities, Drug-Induced; Acetates; Amines; Anticonvulsants; Australia; Cross-Cultural Comparison | 2001 |
Gabapentin-induced anorgasmia in women.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, D | 2002 |
Comparison of gabapentin with other antiepileptic and GABAergic drugs.
Topics: Acetates; Action Potentials; Amines; Animals; Anticonvulsants; Carbamazepine; Cats; Cyclohexanecarbo | 1991 |
Mechanisms of action of new antiepileptic drugs.
Topics: Acetamides; Acetates; Amines; Aminocaproates; Aminopyridines; Anti-Anxiety Agents; Anticonvulsants; | 1989 |